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Abstract 
Polymorphism can influence every aspect of the properties of a solid including the 
shelf life, dissolution rate, solubility, formulation properties and processing properties 
of a solid drug. A deeper understanding of polymorphism and related solid state 
properties would ensure an improved quality of the materials used throughout drug 
preparation, dosage form formulation and clinical trials. Therefore, determination of 
the existence of polymorphs and pseudopolymorphs, characterization of different 
solid state forms and their respective properties, and controlling the existing form in 
the resulting formulation all form part of a rapidly growing field within 
pharmaceutical research and industry. 
Carbamazepine (CBZ) was the model drug used in this study. FT-Raman 
spectroscopy was chosen as a main investigative technique in this study to evaluate its 
potential in monitoring (pseudo)polymorphic conversions in aqueous suspensions in 
the absence or presence of various pharmaceutical excipients. Partial least squares 
analysis (PLS) was used for quantitative analysis of the spectral data. 
Earlier it has been found that CBZ converts rapidly to the dihydrate (DH) when 
exposed to humidity or water, and this has been reported to be the main reason for the 
sometimes observed greatly decreased bioavailability of marketed CBZ tablets. In this 
study, the conversion kinetics of CBZ (forms I, II and III) to DH in aqueous 
suspension were found to be first order kinetics with an unconverted portion (R2 2:: 
0.95), where the crystal morphology appeared to play a more important role in its 
conversion kinetics than the polymorphic form. The influence of pharmaceutical 
excipients on the conversion of CBZ in aqueous suspension was also explored. For 
excipients such as methylcellulose (MC), hydroxypropyl methylcellulose (HPMC) 
and hydroxypropyl cellulose (HPC) which have both a low solubility parameter ( < 
27.0 MPa112) and strong hydrogen bonding groups, complete inhibition of the 
conversion of CBZ was possible even at a very low concentration (0.1 % w/v). 
Raman spectroscopy showed its high applicability in investigating CBZ conversion 
kinetics and screening of excipient effects in aqueous environment. It was 
demonstrated that Raman has a robust nature in quantitative analysis since problems 
such as different particle size, morphology, and spatial distribution of the two solid 
state forms of the drug seemed not to have significant influence on Raman scattering. 
This study has also clarified the relative importance of many contributing factors 
(type of crystalline form (CBZ or DH), crystal morphology, surface area, and 
excipient interactions with drug particles) influencing the in vitro dissolution of CBZ. 
The solid state characterization approach taken in this study will provide a deeper 
insight into the dissolution performance of drugs and should thus lead to a better 
understanding of in vitro/in vivo behavior of drugs. 
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1.1 General introduction: the importance of polymorph investigation 
Polymorphism has been widely observed in pharmaceutical compounds since the 
1960s, but only about thirty to forty years later it began to grow as an important 
research area for both pharmaceutics and pharmaceutical chemistry [1]. Whilst 
initially polymorphism was described as a "strange and unusual phenomenon" [2] 
which fascinated a number of chemists and pharmaceutical scientists it has now 
became a "mature" field within the pharmaceutical research. 
Polymorphism of pharmaceutical solids today receives a great deal of scrutiny 
throughout various stages of drug product development, manufacturing and regulation 
[3, 4]. Polymorphism of drug substances has also demonstrated an increased 
imp01tance in IP issues and patenting. The serious consequences from lack of 
knowledge of polymorphism are demonstrated for example by the well known case of 
ritonavir in 1998. A new polymorphic form of ritonavir (called form II) appeared 
during the manufacture of Norvir capsules both in the bulk drug and the formulation. 
Form II in the final product dramatically lowered solubility compared to the previous 
form and resulted in failed dissolution tests of the capsules. This led to product 
development delay and disruption of commercial production [5]. Because of the 
essential importance of polymorphism to both pharmaceutical research and industry, 
the definition of polymorphism and the current state of knowledge in this area are 
described in detail in the following text. 
1.2 Theoretical concepts of polymorphism 
The theories of polymorphism have been reviewed in a number of classic and recent 
books [2] [6]. According to Bernstein, molecular crystalline polymorphism is defined 
as the presence of polymorphic structures of molecular crystals which have different 
phases of a particular molecular entity. For an insight into the formation of these 
phases and relationships between different polymorphs, the understanding of three 
classic tools is essential: the phase rule, and the thermodynamics and kinetics of 
polymorphic molecular crystals. 
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1.2.1 The Phase Rule 
The Phase Rule was deduced from thermodynamic principles by Gibbs in the 1870s 
[7, 8]. It describes the possible number of degrees of freedom in an equilibrated 
system, in terms of the number of separate phases and the number of independent 
chemical constituents (components) in the system. The phase rule is simply expressed 
as: 
F=C-P+2 
where: Fis number of degrees of freedom of the system, 
C is the number of components, 
and P is the number of phases. 
(1.1) 
A phase is defined as any homogeneous and physically distinct pa1t of a system 
immiscible with the other parts of the system [9]. One phase could possibly contain 
several chemical constituents, which may or may not be shared with other phases. 
A component is simply a chemical constituent involved in the system. The number of 
components in the equation is the minimum number of independent species required 
to define the composition of all the phases in the system [2]. 
The degrees of freedom are the number of independent intensive variables that need 
to be specified in order to fully determine the state of the system. The commonly used 
intensive variables are temperature, pressure or concentration. 
In a defined polymorphic system, C is a fixed value of 1 since all the polymorphs are 
formed of one component. According to Equation 1.1, the maximum number of 
polymorphic phases (P) that can co-exist in the system is 3 since F can not be 
negative. This con-esponds to a tiiple point. Consequently, when two polymorphs 
coexist in the system, F is 1, which means the two phases coexist with either the vapor 
or liquid phase, but not both. The understanding of the phase rule in terms of 
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polymorphic system is imp01tant for evaluating thermodynamic relationships between 
all the existing polymorphs in the system. 
Systems containing solvates or hydrates are more complicated than a polymorphic 
system. The substance itself is a component, and the solvent (or water) comprises a 
second component. Therefore, the number of components in the solvate or hydrate 
systems is more than one. According to Brittain, the general rule for determining the 
number of components is to choose an equilibrium situation where the smallest 
number of the species is needed to express the concentration of each phase 
participating in the equilibrium [6]. 
1.2.2 Thermodynamic properties of crystalline phases 
The existence of a ce1tain crystalline form/phase at a defined condition is specified by 
the thermodynamic prope1ties of the crystalline phase involved. The most likely 
existing form at a defined condition is the form which has the lowest free energy and 
thus is the most stable form at this condition. However, the structure or composition 
of the existing crystalline phase may change when the environmental conditions e.g. 
temperature and pressure change, and this is called a phase transition. 
The well known equation developed by the American mathematical physicist Willard 
Gibbs in the 1870s, describes the free energy of the system as shown below: 
G = H - TS = E + PV - TS (1.2) 
Gibbs free energy (G) is defined by enthalpy (H) and entropy (S), where T is the 
absolute temperature, Pis the pressure, Vis the volume, and Eis the internal energy. 
The thermodynamic relationships between polymorphs can be easily explained based 
on Equation 1.2. At a certain set of environmental conditions, the polymorph having 
the lowest free energy ( G'metastabte > Gstabte) is the most stable one. If G' 111e,asrable = Gs,able 
under ce1tain P and T conditions, then a reversible phase transition can take place and 
this phenomenon is called enantiotropy. If however, G'111e,astabte > Gs,abte, at all values of 
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P and T, only the metastable form can transform to the stable form. This situation is 
termed monotropy. Polymorphic systems may thus be described as enantiotropic or 
monotropic. 
The relative stability of the different polymorphic forms or phases of a polymorphic 
system is of vital importance for all steps of drug and dosage form development 
beginning with polymorph screening and formulation selection. Therefore, a number 
of empirical rules have been developed in an attempt to deduce the relative order of 
polymorph stability. The ones often applied in the pharmaceutical area are the heat of 
transition rule [10, 11] and heat of fusion rule [12, 13]. The heat of transition rule can 
be easily explained referring to the Gibbs free energy (energy vs temperature) 
diagram. According to the heat of transition rule, in the Gibbs free energy diagram, 
the crossing of the free energy curves of the forms indicates the transition points 
between the forms. If this transition point is lower than the melting temperature of the 
lower melting form in the system, this system is defined as an enantiotropic 
polymorphic system. For a monotropic system, however, the free energy curves do 
not cross and thus no transition point would be observed at a temperature below the 
melting point of the lower melting form. 
The heat of fusion rule, as its name states, is related to the heat of fusion of the 
polymorphic pair. In an enatiotropic system, the higher melting form will have the 
lower heat of fusion. If the higher melting form has a higher heat of fusion, the forms 
are monotropically related. 
1.2.3 Kinetic factors in crystallization 
1.2.3.1. Nucleation 
The kinetic factors in crystallization include two main processes: formation of nuclei 
(nucleation) and growth of these nuclei into visible size (crystal growth). Nucleation 
is a process where a phase boundary exists between the solid and liquid phase, and 
energy is needed to overcome the boundary between the solid and liquid phase. The 
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degree of energy needed depends on the size of the nuclei, which act as centres of 
crystallization. 
This classic theory was developed by Volmer in 1939, and still remains useful today 
[14]. Following this theory, the formation of crystal nuclei (crystal clusters of a 
critical size) is a key factor for the nucleation, and further molecular additions to this 
critical cluster results in the subsequent growth of the nucleus. The relation between 
the free energy of the system and the critical cluster formation can be understood from 
the diagram shown in Figure 1.1. 
+ve 
-ve 
0 Size of nucleus, r 
Figure 1.1 Free energy diagram showing the relationships between free energy of the 
system and the existence of a critical nuclei size (adapted from [15]): /lG is the 
overall excess free energy; llGs is the surface excess free energy, f'lGv is the volume 
excess free energy and re is the critical nucleus radius. 
As shown by Equation 1.3, the overall free energy, /lG, is calculated from two terms 
which are of opposite sign and depend differently on r (radius of a nucleus) (see 
Figure 1.1). According to Equation 1.3, /lG passes through a maximum, flGcrir which 
corresponds to the critical nucleus radius re. 
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2 4 3 
/.lG = l.lG s + l.lGv = 4nr r + - nr l.lGv 
3 
where: /.lG is overall excess free energy, 
l.lGs is sum of the surface excess free energy (a positive quantity), 
l.lGv is volume excess free energy (a negative quantity), 
and y is surface free energy. 
(1.3) 
This also relates to factors such as supersaturation (Section 1.3.3.1): the higher the 
level of supersaturation the smaller the size of the critical cluster. Also for a particular 
solution composition, if the critical size is lower for polymorph II than for I, then the 
activation free energy for nucleation is lower and kinetics will favour form II. The 
rates of nucleation for a dimorphic system consisting of polymorph I and II were 




Figure 1.2 Schematic solubility diagram for a dimorphic system showing a 
hypothetical crystallization pathway (vertical atrnw) at a constant temperature 
(adapted from [2]). 
According to the classic nucleation equation (Equation 1.4), there are several other 
factors such as surface free energy, temperature and solubility which can also 
influence the nucleation rate. The nucleation rate (J) is expressed as [15]: 
7 
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where: J is the number of nuclei formed per unit volume, 
A11 is pre-exponential factor (solubility), 
y is the surface free energy, 
vis the molecular volume, 
k is the Boltzmann's constant, 
Tis the temperature, 
and CJ is the degree of supersaturation. 
1.2.3.2. Crystal growth 
(1.4) 
As soon as stable nuclei have formed, they begin to grow into crystals of visible size, 
a process called crystal growth. A number of theories have been proposed for 
explaining the phenomenon of crystal growth. The most widely known ones are the 
surface energy theory and the adsorption layer theory. The surface energy theory was 
introduced by Gibbs in 1878 [16] and assumes that the growth rate of a face is 
inversely proportional to the lattice density of the respective lattice plane. In other 
words, the face having the lowest lattice density grows the fastest and could 
eventually disappear. This also results in geometric dissimilarity of the grown crystals 
since the smaller, faster-growing faces are often eliminated [15]. 
It is known that solvents can have a significant influence on the external crystal shape 
and size of the crystallized solutes. A possible link between solvent prope1ty and 
solute morphology has been suggested by several authors where the hydrogen 
bonding interactions between the solute and solvent were found to have an important 
impact on the resulting crystal morphology. It has also been reported that the 
solubility parameter value of the solute was likely to be related to the crystal size 
where solutes having higher solubility parameter values tend to form larger crystal 
size [ 17, 18]. 
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The adsorption layer theory assumes there is an adsorbed layer of solute molecules on 
a crystal face. When units of the crystallizing substance arrive at the crystal face they 
are not incorporated into the crystal lattice immediately instead they lose one degree 
of freedom and migrate over the crystal face. There will, therefore, be a loosely 
adsorbed layer of crystallizing units at the interface between the crystal face and the 
bulk solution. This adsorption layer can be very thin (about 1 nm). Once the 
adsorption layer is formed, further growth units would keep linking into the lattice of 
the adsorption layer in positions where the attractive forces are greatest, and 
eventually build up a whole face plane [15]. 
The Kassel model [19, 20], the first theoretical model of crystal growth, is based on 
similar assumptions as the adsorption layer theory. As shown in the diagram below, 
the Kassel model envisages some kink sites located in an apparently flat surface, and 
the growth units are most likely to be incorporated into these kinks; the kinks move 
along the step and the face is eventually completed [20]. 
Figure 1.3 Kassel' s model of a growing crystal faces: flat surfaces (P and P'); steps 
(S and S'); kink sites (K). The transport of a growth unit is as follows: adsorption to 
the surface (A); diffusion to reach the step (B); and one-dimensional diffusion along 
the step to a kink (C) (adapted from [20]). 
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1.2.4 Structural aspects of polymorphism 
A crystalline species is defined as a solid that is composed of atoms, ions or 
molecules arranged in a periodic, 3-dimensional pattern [21]. A 3-dimensional affay 
is called a lattice (Figure 1.4), where each smallest periodic volume is termed the unit 
cell. A unit cell is defined by the lengths of the crystal axes a, b, and c and by the 
angles a, ~ and y between these. A unit cell taken from the lattice and depicted with 
vectors is shown in Figure 1.5. 
Figure 1.4 Three-dimensional lattice (solid circles represent the lattice points) 






Figure 1.5 A unit cell with cell dimensions depicted as vector (adapted from [22]). 
Seven crystal systems can be differentiated on the basis of unit cell types. These are 
listed in Table 1-1. 
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Table 1-1 Seven crystal systems. 
Crystal System Axial lengths and angles 
Cubic a = b = c; a = ~ = y = 90° 
Tetragonal a = b i= c; a= ~ = y = 90° 
Orthorhombic a i= b i= c; a = ~ = y = 90° 
Trigonal (Rhombohedral) a = b = c; a = ~ = y i= 90° 
Hexagonal a= bi= c; a= ~ = 90°, y = 120° 
Monoclinic a i= b i= c; a = y = 90° i= ~ 
Triclinic a i= b i= c; a i= ~ i= y i= 90° 
The French crystallographer, Bravais, demonstrated in 1848 that there are fourteen 
possible point lattices. These fourteen Bravais lattices are the result of combining the 





























Figure 1.6 The fomteen Bravais lattices (adapted from [23]). 
C 
All crystals can be assigned to one of the seven crystal systems and to one of the 14 
Bravais lattices. Therefore, the crystal system and the types of lattices provide an 
impottant method for classifying and investigating the internal structure of any 
unknown crystal. 
1.2.4.1. Packing and conformational polymorphism 
Polymorphism arises when a crystalline substance having the same elemental 
composition crystallizes in different crystal packing arrangements and/or 
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conformations. Different polymorphs have different unit cells and thus have different 
physicochemical properties [6]. 
The structure of different modifications of an organic molecule can be divided into 
two main groups. If the molecule is constrained to exist as a rigid grouping of atoms, 
these may be stacked in different ways to occupy the points of different lattices. This 
type of polymorphism is classified as packing polymorphism. On the other hand, 
when the molecule is not rigidly constructed it can exist in distinct conformational 
states. This type of polymorphism is then called conformational polymorphism [24]. 
1.2.4.2. Pseudopolymorphism 
According to the available definitions from the works of McCrone [25], Threlfall 
[26], Bernstein [27] and Nangia [28], pseudopolymorphs are crystals formed of the 
same substance but with different amounts or types of solvent molecules. However, 
the use of the term pseudopolymorphism has been encouraged to be abandoned by 
Bernstein due to its confusion in describing solvates. A simple example was also 
demonstrated by Bernstein, for the solvates of the same compound but different 
crystal structure, it is clearer to define them as polymorphs of a solvate rather than 
polymorphs of psuedopolymorphs [27]. Nevertheless, a number of solvents, for 
example methanol, ethanol, acetone and water have been reported to be incorporated 
into the crystal lattice of drug substances thus forming solvates [25]. Since water is an 
ubiquitous substance, the most commonly existing pseudopolymorphs are hydrates, 
which are formed when the incorporated solvent is water [29]. 
According to the different connecting mechanisms between the incorporated water 
molecules and molecules in the crystal lattice, hydrates have been classified into three 
main classes [6]: 
I. Isolated lattice sites 
2. Lattice channels 
a. Expanded channels (non-stoichiometric) 
b. Lattice planes 
c. Dehydrated hydrates 
13 
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3. Metal-ion coordinated water 
The detailed characteristics of each hydrate class and also typical examples of these 
hydrate classes have been reported in several books [2] [6]. Briefly, the hydrate 
species in the isolated lattice sites have a structure where water molecules are isolated 
from direct contact with other water molecules by intervening drug molecules. 
Therefore, no network of hydrogen bonds exists only involving water molecules on 
any axis through the crystal. Upon dehydration of the hydrate, water molecules on the 
surface of the hydrate may be easily lost, but the creation of a hole in the hydrate does 
not leave other water molecules accessible. In channel hydrates, the incorporated 
water molecules line up along an axis of the crystal lattice, and thus fo1m channels 
through the crystal. The DSC thermographs of channel hydrates always show a broad 
peak around 100 °C indicating a continuous water loss. This is because the water 
molecules are connected to each other, where the loss of the first water molecule on 
the surface of the channel ends creates a channel for the next and sets up a 
thermodynamic gradient in the same direction. The metal-water interaction in class 3 
hydrates can be quite strong compared with the other water bonding in a molecular 
crystal. Therefore, dehydration of class 3 hydrates usually requires higher 
temperatures than for hydrates in the other classes. 
1.2.4.3. Internal and external crystal structure 
The arrangement of molecules in a crystal or its internal structure determines its 
polymorphic form and its external structure reflects its morphology. Ideally, the 
morphology of a crystal is closely related to its internal symmetry. However, the same 
polymorph can have very different morphologies depending on the influence of both 
internal and external factors. Internal factors include crystal structure and crystal 
defects which determine the nature and strength of the intermolecular interactions in 
the crystal. External factors include temperature, degree of supersaturation, solvent 
type, presence of impurities etc.[15]. 
The investigation of crystal morphology is of importance for revealing molecular 
interactions occurring at the crystal liquid interface. More importantly, both internal 
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and external structures of a c1ystal can influence its physical properties such as 
flowability, compressibility, dissolution rate and solubility. In some cases, even 
chemical properties may be affected [30, 31]. The importance of internal crystal 
structure (polymorphism) as well as external shape (crystal morphology) on the 
physical properties of crystals (here: hydrate formation kinetics) will be highlighted in 
the studies presented in Chapter 2. 
1.2.5 Crystalline phase transformation 
Changes in the external parameters (conditions) such as temperature and pressure can 
induce polymorphic transformations. These transformations can be classified into four 
groups: solid state phase, solution mediated, melt mediated and interface mediated 
transformations [32]. 
As the transformation of carbamazepine to its dihydrate in aqueous suspension is the 
focus of this thesis, and has been found to be of the solution mediated type, only 
solution mediated transformation is described here. The solution mediated 
transformation process often involves three steps: 1. dissolution of the less stable 
form; 2. formation of nuclei of the stable form; 3. recrystallization/growth of the 
stable form. The different solubilities of the two forms are the driving force for the 
transformation and transformation rates can be influenced by various kinetic factors 
such as the difference between the solubilities of the two forms, solvent type, 
temperature, stirring rate and presence of impurities. 
1.3 Analytical techniques 
Various analytical techniques are available for characterizing pharmaceutical solids. 
Since different polymorphs have different internal crystalline structures which could 
lead to differences in virtually every physicochemical prope1ty, many techniques can 
be used in principle for differentiating or characterizing polymorphs. However, the 
sensitivity of each technique to the differences among different types of polymorphs 
can be different. As a general rule, a combined use of a wide range of techniques is 
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usually the best way to obtain a thorough understanding of drug polymorphism. In the 
following paragraphs, several commonly employed polymorph characterization 
techniques will be introduced. The principles of these techniques will only be 
described briefly since the intent of these paragraphs is to summarize and emphasize 
the application and potential of these techniques in pharmaceutical research and 
industry. These techniques have been classified by Brittain (1995) according to their 
detection level as molecular, particulate and bulk techniques [3]. 
1.3.1 Characterization at the molecular level 
There are several commonly employed molecular motion probing techniques as listed 
below. A better understanding of these techniques may be gained by starting at the 
basic physical theories. 
Atomic and molecular spectra are generated from the interaction of electromagnetic 
(EM) radiation and matter. Three types of interactions are commonly encountered: 
emission, absorption and scattering. The observation of discrete spectra from atoms 
and molecules can be pictured as the atom or molecule generating a photon of energy 
hv when it discards an energy of magnitude LlE, with LlE = hv. The EM wave has both 
electric and magnetic fields oscillating in phase at the same frequency and 
wavelength, but perpendicular to each other. 
Molecules have three main types of motions: translational, vibrational and rotational. 
All molecules can be imagined to exist in different energy levels, and the transitions 
between rotational/vibrational energy levels gives Iise to their rotational/vibrational 
spectra respectively. 
In the following section we will only focus on the vibrational motion of molecules as 
this is of higher importance for polymorph investigation. The motion of a diatomic 
molecule can be modeled as a harmonic motion since most mass of an atom is at the 
nuclei, and thus the covalent bonds can be regarded as a spring. The spring 
stretching/compression obeys Hooke's law. Therefore, the energy of a harmonic 
oscillator at a defined vibration energy level (Ev) is Ev= (v + Vz) hro where the energy 
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level (v) is equal to 0, 1, 2, etc., and co is the frequency of the oscillation. Thus, the 
energy between every adjacent level is 
M = Ev+! - Ev = hOJ (1.5) 
The energy levels of a harmonic oscillator are evenly spaced as shown in Figure 1.7. 
PE 
0 X 
Figure 1. 7 The plot of potential energy (PE) versus internuclear distance (x), v stands 
for energy level. 
Vibrations in polyatomic molecules involve complex movements of their constituent 
atoms, and the vibration energy of the molecule is the sum of the energy of individual 
atoms. In practice, molecule vibrations are usually non-harmonic, i.e., vibrations 
about the equilibrium position are non-symmetric. The spacings between energy 
levels are not identical but rather decrease with increasing energy. 
The three commonly used spectroscopic techniques, infrared, near-infrared and 
Raman spectroscopy are all based on molecular vibration. However, each technique 
makes use of different responses of the molecular vibration to the incident light. The 
basic theory including the laser sources and excitation conditions of each technique 
and also their applications with respect to the experimental aspects have been 
summarized by Siesler et al. as shown in Figure 1.8 [33]. 
17 
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Figure 1.8 Diagram showing the specific features of Raman, mid-infrared and near-
infrared spectroscopy (adapted from [33]). 
1.3.1.1. Near-infrared spectroscopy 
Several books and review articles have described the principle of near-infrared (NIR) 
spectroscopy in detail [34] [35] [33, 36-38]. 
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The near-infrared (NIR) lies between the visible and mid-IR regions of the 
electromagnetic spectrum and contains absorption bands originating from overtones 
and combinations of fundamental vibrations observed in the mid-IR region (as 
presented in Figure 1.8) [33, 39]. The commonly observed bands in the NIR region 
are OH, CH, NH and SH bands where hydrogen is bonded to a heteroatom and thus 
there is a large mass difference between the two atoms. For the bonds connected by 
atoms of similar mass, the frequency of their combinations and first overtones often 
fall within the IR region, and are obscured by the stronger, primary absorbance peaks. 
Therefore, NIR bands are not found for bonds without a hydrogen atom and also they 
are always broadly overlapping and weaker than the intensities of the fundamental IR 
bands [40]. Neve1theless, NIR has its unique advantages and has been widely 
employed in various areas of science for example pharmaceutical sciences, food 
science [41], forest [42], biomedical [43] and chemical industries [44]. 
The pharmaceutical applications of NIR spectroscopy and also its potential as a 
process analytical technique (PAT) in pharmaceutical industry have been reviewed 
recently [45] [46, 47]. NIR instruments can be utilized for identification and 
quantification of polymorphs [ 48-50] for determining the active phannaceutical 
ingredient in tablets, where tablets of several millimeters thickness can be measured 
when a transmission mode is employed [51] [52]; for monitoring particle size and the 
blending processes since the effects of scattering and absorption both contribute to the 
penetration depth of the light into the sample, and are directly related to the effective 
particle size of the sample [53, 54]; for determining moisture content and also for 
identifying and quantifying the polymorphic form of the drug in water containing 
formulations such as aqueous suspensions [55, 56]. 
1.3.1.2. Infrared spectroscopy 
There is no shortage of reviews and books describing the principles of infrared (IR) 
spectroscopy in depth [57-60]. In brief, IR spectroscopy probes the absorption 
originating when an organic molecule is exposed to infrared radiation, and the radiant 
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transition energy levels in IR are shown in Figure 1.8 and described by Equation 1.5. 
There are 2n - 6 (where n is the number of atoms) allowed vibrations in nonlinear 
molecules, each with a defined LlE. The intensity of IR absorption depends on the 
molecular vibration interacting with the dipole moment induced by the 
electromagnetic radiation. Polar groups generally absorb IR radiation much more 
strongly than nonpolar bonds since their nuclear vibrations involve a larger change in 
their dipole moment [61] [62]. 
The commonly employed IR modes for polymorph characterization are attenuated 
total reflection (ATR) and diffuse reflectance IR spectroscopy (DRIFTs), as well as 
IR microscopy (imaging and spatially localized spectra) [63]. When using these 
methods, no high mechanical energy input such as grinding and compression is 
required in the sample preparation. Therefore, there is a low risk of polymorphic 
transformation, making them the preferred methods in IR spectroscopy investigations 
of polymorphism and crystallinity [64]. The application of IR spectroscopy in 
pharmaceutics and its potential have been at the centre of several reviews [65, 66]. IR 
can be used both off-line (i.e. to determine polymorphic forms) [67] but also on-line 
to monitor the crystallization process [68]. The advantages and limitations of IR in 
comparison with Raman spectroscopy will be discussed in the following section. 
1.3.1.3. Raman spectroscopy 
The energy levels explored by Raman spectroscopy are the same as those in IR 
spectroscopy. However, the two techniques are based on different molecule 
vibrations. Molecules must have a dipole moment change to be IR activate, while 
their polarity must change (i.e. their induced dipole moment) to be of Raman active. 
Therefore, information obtained from Raman and IR are complementary, however 
some vibrational modes may be both Raman and IR active [69]. 
Raman spectroscopy has only recently arisen as one of the commonly used molecular 
motion probing techniques. The invention of Raman spectroscopy goes back to 1928 
when the Indian physicist C.V. Raman first found that the wavelength of a small 
fraction of the radiation scattered by certain molecules differs from that of the 
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incident beam. This discovery led Raman to be awarded the Nobel Prize in Physics in 
1931. 
The electric field of the electromagnetic radiation in the vicinity of the molecule 
varies with time. The amplitude of the oscillating electric field can be represented by 
(1.6) 
where E0 is a constant, the maximum value of the field, VL is the laser frequency, and t 
is time. 
When a molecule is put into an oscillating electric field, it gets some distortion, the 
positively charged nuclei being attracted towards the negative pole of the field and the 
electrons to the positive pole. This separation of charge centers causes an induced 
electric dipole moment (P) to be set up in the molecule and the molecule is said to be 
polarized. This induced dipole moment is 
P=aE (1.7) 
where a. is the polarizability, which can be regarded as the deformability of the 
electron cloud of the molecule by the electric field. It has to be mentioned that a is not 
a constant with respect to P because the molecule vibrates even at v = 0. The variation 
of polarizability of molecules (a.) with rotation is 
a=ao +(aaJ q oq a (1.8) 
where a.0 is the equilibrium polarizability, q is a normal coordinate, and 0%q is the 
rate of change of polarizability with respect to qo. The normal coordinate q varies 
periodically as presented by the equation below 
q = % cos(2.nvvibt) (1.9) 
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where Vvib is vibrational frequency of the molecule, and qo is a constant, normal 
coordinate at the equilibrium position. Combing the Equations 1.8 and 1.9 
(1.10) 





According to a trigonometric identity ( cos A cos B = - { cos(A + B) + cos(A - B)} ), 
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Equation 1.12 can be written 
P - a0E0 cos(2Jrv ,t) +-H ( ~: l q,E,[ cos(21'(v, + v "'" )t) cos(2Jr(v,. - v "" )t)} (L 13) 
It can be seen from Equation 1.13 that the induced dipole moment P varies with three 
components VL, VL - Vvib, VL + Vvib· These components are time dependent, and give rise 
to Rayleigh scattering ( cos(2nv J) ), Stokes scattering ( cos(2.n-(v L + v vib )t)) and 
anti-Stokes Raman scattering ( cos(2.n-(v L - vvih )t)) respectively. The intensity of a 
Raman scattering is given by (aaJ qE
0
• As seen from this formula, the intensity of aq o 
Raman scattering is not related to the external electric field, but depends on the 
chemical structure of molecules responsible for the scattering. There are three main 
aspects that influence the Raman scattering: mass of atoms vibrating, nature of the 
chemical bonds, and physical effects on the chemical bonding such as crystallinity or 
polymorphic form. These aspects, especially the third one, make Raman spectroscopy 
an important method for the purpose of polymorphic investigations. 
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Figure 1.9 shows a schematic of a simple Raman instrument. It consists basically of 
three parts: the radiation source, the dispersing element or diffraction grating and the 
detector. The source of radiation is usually a laser (light amplication by stimulated 
emission of radiation). In Raman spectroscopy, the laser wavelengths used range from 
the ultraviolet to the near-infrared region. Since Raman scattering is relatively weak 
Cis (intensity of scattering) = In. 4 (A is wavelength of incident light)), a highly 
powered radiation source is needed. However, this also leads to two commonly 
known disadvantages of Raman spectroscopy, i.e. intense fluorescence from 
contaminants or the sample may be induced, and also photodegradation can be seen 
for some samples. The introduction of Fourier transformed Raman spectroscopy (FT-
Raman) greatly facilitated the popularity of Raman spectroscopy since lower energy 
sources such as the He/Ne laser, or NIR sources (e.g. Nd/YAG laser) can then be 
used. 
The detector in Raman spectroscopy usually has to be highly efficient since the 
scattered light intensity is low. Cooled charge coupled device (CCD) arrays are thus 
used in FT-Raman. The connection between the radiation source and the detector is 
the dispersing element or diffraction grating. It has many fine grooves inducing 
interference between waves reflected from its surface, and constructive interference 
occurs at specific angles that depend on the frequency of the radiation being used. 
Figure 1.9 The basic setup for a Raman spectrometer (adapted from [61]). 
Although the information from IR and Raman spectroscopy are complementary, there 
are some advantages of Raman over IR, including simple (or no) sample preparation, 
23 
Chapter 1 Introduction 
low scattering of water, and the possibility of using glass and plastic cells. Also, 
Raman spectroscopy is often easier to use in the experimental praxis for identification 
of chemicals, as there are usually fewer peaks. Therefore, Raman spectroscopy is 
especially useful for biological samples and samples containing water. However, 
pharmaceutical applications of Raman spectroscopy in investigating water related 
formulations such as suspensions, microemulsions and wet granulations are still rare 
[70-75]. The potential of Raman spectroscopy in particle sizing, tablet analysis and 
polymorphic identification has been demonstrated recently when in-line 
measurements using fiber optic probes and compact spectrometers for remote analysis 
have became available [71, 76, 77]. Furthermore, Raman can be used for identifying 
the molecular symmetry and orientation of single crystals. This application however is 
much more complicated as the polarization components depend on the orientation of 
the crystal axes with respect to the plan of polarization of the incident laser, as well as 
on the relative polarization of the input and observing polarizer [78]. 
Another potential advantage of Raman spectroscopy is that it can be used for probing 
the lattice vibrations that are associated with a molecule in the crystalline state. These 
lattice vibrations correspond to the translationary and rotatory motion of the entire 
molecule within the crystal lattice, and are usually in the range of 400 - 10 cm-1. 
Although these vibrations modes are both Raman and IR active [79, 80], they are 
hardly reached by an IR spectrometer. McMahon et al. have used the low 
wavenumber region in the Raman spectra for showing different CBZ DH lattice 
vibrations when different CBZ polymorphic forms were used as starting material [25]. 
Also, Bellows et al. have used the lattice vibration differences in Raman spectroscopy 
between ampicillin and griseofulvin for their identification [81]. Recently terahertz 
pulsed spectroscopy has been developed to a readily usable state, to be more specific 
at probing low frequency bond vibrations, long-range crystalline lattice vibrations and 
hydrogen-bonding stretches in solid materials. The pharmaceutical applications of 
terahertz pulsed spectroscopy especially in investigating the levels of crystallinity and 
polymorphism of pharmaceutical materials have been reported in a number of 
publications [82-85]. 
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1.3.1.4. Magnetic resonance spectroscopy 
Magnetic resonance spectroscopy (NMR) probes the information on the level of the 
nuclei of the atoms and thus allows identification of individual atoms in a molecule. 
The chemical environment of specific nuclei is deduced from information obtained 
about the nuclei. When a material is put in a magnetic field, the nuclei of the atoms of 
this material in a lower energy level may be excited to a higher level by the 
electromagnetic radiation of an appropriate wavelength (in the radio frequency range). 
The theoretical basis and applications of NMR in solid state investigations has been 
reviewed in a number of references [2, 3, 79, 86]. 
NMR has gained an increasing interest for differentiating and quantifying 
polymorphic systems since the molecules in different polymorphs have different 
crystal environments where at least some atoms should have specific NMR signals 
thus enabling application in polymorph detection. NMR has been used for 
investigating CBZ, the model drug used in this thesis, in both solid state and hydrogel 
formulations [87]. Also, modelling of NMR spectra of various CBZ polymorphs and 
its solvates has been reported where CBZ molecular arrangements have been probed 
by combining both experimental and calculated data [88]. 
1.3.2 Characterization at the particulate level 
1.3.2.1. X-ray diffraction (XRD) 
For every crystal, the atoms can be assumed to be arranged in a periodic three 
dimensional arrangement, therefore, there are defined crystalline lattice and thus 
planar spacings. According to Bragg's model (Figure 1.10) constructive interference 
happens when the path length between these two successive planes equals nA, where 
the path length is 2dsin8. 
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Figure 1.10 Reflection of X-rays according to Bragg's model (adapted from [89]). 
Bragg's law thus states: 
Where: n = order of reflection 
A = wavelength 
2dsinB = nA (1.14) 
d = distance between the planes in the crystal, expressed in angstrom units 
8 = angle of incidence of the X-ray beam 
Single X-ray crystallography is the gold standard technique for polymorphism 
investigations as it is directly related to the planar spacing of polymorphs. However, 
the application of single crystal X-ray diffraction has been greatly limited by its strict 
sample requirements for instance the availability of high-quality single crystals of 
suitable size, which in practical terms can be very difficult to achieve [90]. 
X-ray powder diffraction (XRPD) has thus been more widely applied than single 
crystal X-ray crystallography in polymorph detection and quantification. In X-ray 
powder diffractometry, the X-ray tube and associated electronics are used to produce 
a limited frequency range of high-intensity X-rays. Figure 1.11 shows a typical X-ray 
tube. 
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Figure 1.11 A schematic of an X-ray tube (adapted from [91]). 
The electrons are generated by a current typically set in the range of 25 - 40 mA from 
a tungsten filament (bottom of the tube, not shown in the diagram) as indicated by the 
arrow (e). The anode is a pure metal; usually Cu, Mo, Fe and Cr are used in XRPD 
instruments. A high voltage (30 to 40 kV) is usually maintained on the anode, and the 
generated electrons are accelerated and interact with the anode to produce a 
characteristic X-ray wavelength for each anode material. 
Cooling water is continuously circulated through the X-ray tube as shown in Figure 
1.11 in order to keep operating temperatures low. Also, thin Be windows are used to 
allow the generated X-rays to exit in the direction of the specimen and maintain the 
vacuum in the tube. 
The produced X-rays are collimated and directed onto the sample at varying angles. A 
detector then detects the X-ray signal following positive interference with the 
crystalline material; the signal is processed either by a microprocessor or 
electronically, converting the signal to a count rate. 
XRPD has the advantages of being able to be used for any types of powder samples, 
being usually non-destructive in nature and providing direct information on the long-
range order of crystals. For crystalline samples, according to Equation 1.5, the 
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diffraction of X-rays by the crystalline lattice may result in constructive interference, 
and every plane would have its unique Bragg angle for the scattering. An amorphous 
form on the other hand lacking definite crystal planes (no long range order) cannot 
yield any constructive interference and thus only shows the typical "halo" in its X-ray 
pattern. 
The main disadvantages of XRPD are that it cannot provide any chemical information 
and no information about the atoms positions in the molecule. Also, absorption of X-
rays can be a problem especially for samples with very small particle size. For a 
mixture of crystalline drug and excipients, overlapping peaks of the drug and 
crystalline or partially crystalline excipients is a common problem for analyzing drug 
products. Furthermore, preferred orientation is common problem in XPRD. The 
possible influence of preferred orientation on quantitative XRPD has been 
investigated in this study and the findings will be presented in Chapter 7. 
1.3.2.2. Microscopy 
Although light microscopy has been known for a longer time than most of the other 
solid state techniques, with the development of other characterization techniques, its 
application has been mostly limited to provide complementary information. This is at 
least partially due to its "subjective" nature and to difficulties in performing 
quantitative measurements. 
The most commonly applied microscopic technique in polymorphism characterization 
is polarized light microscopy (PLM), where the appearance of light/color indicates the 
presence of birefringence ( crystalline or liquid crystalline samples 1) and variations in 
size, shape or color may provide information about the homogeneity or diversity of 
the sample. A number of high-quality books and review articles on PLM have been 
published [92-94]. A hot stage is a useful accessory for PLM, and is most widely 
utilized in the observation of phase transitions such as a solid-solid transition where 
discontinuous changes in polarization colours under heating are an indication of the 
1 An exception are cubic crystals and liquid crystals which are isotropic and hence do not lead to 
birefringence. 
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transition. A wealth of information about desolvation/dehydration transformation can 
also be readily obtained using the hot stage PLM technique. For instance, information 
as to whether the nucleation of the new phase is occurring randomly or crystal face 
dependent, or if the phase change occurs throughout the crystal in a diffuse manner or 
at certain edges and then moves through the crystal may be obtained [2]. Often, these 
optically detected events may barely be detectable using other analytical techniques 
such as differential scanning calorimetry (DSC). 
Another microscopic technique frequently used m polymorphic investigation is 
scanning electron microscopy (SEM), which has widespread utilization due to its 
better depth of field and higher resolution than optical microscopy. In light 
microscopy (and also in transmission electron microscopy), a specimen is viewed 
through a series of lenses that magnify the visible image. However, in SEM, an 
electronic map of the specimen that is displayed on a cathode ray tube (CRT) is 
produced. The theory of SEM is explained in detail by a number of authors [95-97]. 
A schematic diagram of a generic SEM is shown in Figure 1.12. Electrons from a 
filament in an electron gun are directed at the specimen in a vacuum chamber. The 
electron beam forms a line that continuously sweeps across the specimen at a high 
speed. This beam irradiates the specimen which in turn produces several signals 
including X-ray fluorescence, secondary or backscattered electrons. 
The use of SEM in various applications probing morphology has been reviewed by 
Newman and Brittain [98]. SEM is especially useful for the investigation of surface 
properties [2]. Specific examples showing the application of SEM in investigating 
polymorphic conversion and related surface morphology changes of carbamazepine 
anhydrates to its dihydrate will be presented in Chapters 5 and 6 in this thesis. 
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Figure 1.12 Schematic diagram of a generic scanning electron microscope (adapted 
from [95]). 
1.3.2.3. Thermal analysis 
There are two important thermal analysis methods in pharmaceutical area, differential 
scanning calorimetry (DSC) and thermogravimetric analysis (TGA). DSC is the most 
commonly used thermal analysis technique, and has been applied to many materials 
for more than thirty years [3]. The principle of DSC is based on a change in the 
physical state of a material is accompanied by the liberation or absorption of heat [2]. 
Two types of DSCs are normally employed: power-compensation and heat-flux 
DSCs. In a power-compensation DSC, the temperature of the sample and reference 
are controlled independently using separate, identical furnaces. The energy required 
for compensating the identical temperature of the sample and reference is a measure 
of the enthalpy or heat capacity changes in the sample relative to the reference. The 
sample and reference are connected in good thermal contact and enclosed in a single 
furnace in heat-flux DSC. Enthalpy or heat capacity changes in the sample cause a 
difference in its temperature relative to the reference, and the temperature difference 
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is recorded and related to an enthalpy change in the sample using appropriate 
calibration experiments. 
The theory of DSC is explained in detail by a number of authors [99-101]. The 
application of DSC in the pharmaceutical field however is often limited to qualitative 
or semiquantitative analysis, and in most cases it is used as a quality control check 
using the location or magnitude of certain thermal events [ 102-104]. 
The development of modulated temperature DSC (MTDSC) has greatly facilitated 
thermal analysis. MDSC has the advantage of higher resolution and the ability to 
separate reversible, irreversible and overlapping thermal events. MDSC has been 
widely utilized in investigating amorphous systems [105-107]. 
Thermogravimetric analysis (TGA) is an analytical technique which is also based on 
the thermal stability of a material, but it is mainly monitoring the weight changes of 
the material during heating. Therefore, the sample weight is recorded as a function of 
increasing temperature in the TGA measurement. TGA is often used as a 
complementary method to DSC, which is especially useful for investigating volatile 
components. For the pharmaceutical materials such as hygroscopic solids or solvates 
containing physically or chemically bonded volatile components, it has a unique 
advantage in directly and accurately detecting the presence as well as amount of the 
volatile components. 
1.3.3 Characterization at the bulk level 
1.3.3.1. Solubility 
Solubility can be defined as the quantity of the solute dissolved divided by the 
quantity of the solvent or the solution [3]. It is determined by the relative balancing of 
the attractive and repulsive forces between the solid and the solvent. 
The solubility of a drug substance is an important physical property. It can 
substantially influence the performance of the drug formulation, especially in case of 
poorly water soluble drugs. Solubility also plays an important role in the nucleation 
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process (Section 1.2.3.1) since supersaturation is the initial driving force for 
nucleation. Simply speaking, the crystal units aggregate under supersaturated 
conditions, and thus form nuclei. A system is considered as supersaturated when the 
solution is at a higher concentration than the saturation value (saturation refers to the 
state of a system when the solid is in equilibrium with the solution) [108]. There are 
several commonly known factors which can influence the solubility of a solid 
including solvent type, temperature and pressure [3]. 
1.3.3.2. Solution calorimetry 
Solution calorimetry measures the heat of solution during dissolution, and is closely 
related to the activation energy differences of the solid state forms [109, 110]. Since 
the dissolution of amorphous drug is an exothermic event, whereas the dissolution of 
crystalline materials is endothermic, solution calorimetry has been applied to detect 
trace amounts of amorphous material in a predominantly crystalline sample. It has 
been demonstrated that a high limit of detection of about 3 % amorphous material can 
be achieved using solution calorimetry [111-113]. 
1.3.3.3. Water sorption 
Physical properties such as flowability, compaction, hardness, and also chemical 
stability of the solids can all be influenced by moisture. An understanding of the 
water adsorption behaviour of all the ingredients, especially the active ingredient in 
the formulation, is necessary, since water vapor exists in the environment and can 
influence or interact with the ingredients during all stages of drug manufacturing and 
during storage. There are several mechanisms related to water-solid interactions, such 
as physical water adsorption by nonhydrated crystals and hydrogen bonding with 
water forming hydrates as described above. Water sorption is especially likely for 
amorphous materials, and thus influences their physico-chemical properties. The 
detailed description of the theories and methods used for investigating moisture 
uptake of pharmaceutical solids has been presented by several authors [ 114-118]. 
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1.4 Quantitative analysis 
1.4.1 Univariate analysis 
Univariate analysis is a quantitative analytical method based on the assumption that 
there is a direct relationship between two sets of values that can be described by a 
single equation. In most cases, it is based on a single parameter (independent variable) 
of the data such as peak height, area or the ratio of two peak heights or areas and one 
dependent variable, for instance sample concentration. 
Univariate analysis has been widely and successfully employed in most quantification 
studies in the pharmaceutical area. For example, univariate analysis has been used to 
quantify the polymorphic composition of carbamazepine and its dihydrate during 
dispersion in an aqueous suspension using Raman spectroscopy [119]. The 
composition of carbamazepine/dihydrate mixtures has been quantified by combining 
XRPD with univariate analysis [120]. Using thermal data obtained from DSC, 
univariate analysis has also been used in examining the relationship between the heat 
capacity and the concentrations of anhydrate and hydrate forms in their binary 
mixtures [121]. 
The selection of the most useful peak is a very important step in the analysis; 
however, this selection can be arbitrary. Also, if peaks unique to the forms of interest 
are not available, univariate analysis is not possible. This problem often arises in 
complex mixtures such as formulation samples containing several components with 
overlapping spectral peaks. With the development of easily used software, the use of 
univariate analysis has been complemented by multivariate analysis. The following 
section will discuss the basic background of several commonly employed multivariate 
analytical methods. 
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1.4.2 Multivariate analysis 
For spectral data, a whole spectrum always covers thousands of wavenumbers and 
more importantly when measuring a transition process, hundreds of spectra are 
usually taken during the whole process. Therefore, a large amount of information 
could be obtained from the final data, whereas traditional regression methods such as 
univariate analysis could barely include all the statistical parameters. Multivariate 
tools have arisen as a very useful method for analyzing spectral data, where the 
spectral information is related to some analytical property (chemometrics) [122]. 
Chemometrics is the science of relating measurements made on a chemical system to 
the state of the system via application of mathematical or statistical methods and of 
designing optimal experiments for investigating chemical systems [123]. 
There are two main categories of multivariate analysis: classical least squares 
regression (CLS) and inverse least squares analysis (ILS). Both methods are derived 
from Beer's Law as shown in Equation 1.15 below where the spectral response (A;.) is 
directly described by an absorptivity constant (K;J which combines the constituent 
absorptivity coefficient constant (s,.) and pathlength of the light (b), and the 
constituent concentration (C). 
(1.15) 
In practice, some amount of error (E) induced by the analytical instrument, sampling 
and other factors often occurs. Therefore, the Equation 1.15 can be rewritten as: 
(1.16) 
where Ex is the absorbance error, which is the residual error between the least squares 
fit line and the actual absorbance. 
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When the sample contains two constituents, A and B, the absorbances of the two 




where Ca and Cb are the concentrations of the two constituents in the sample, and 
Ka,;.1 and Kb,;.2 are the absorptivity constants at those two wavelengths (21 and 22). E}.] 
and E;.2 are the absorbance errors. 
Because the absorbances of multiple constituents at the same wavelength are additive, 
the two component equations for a single spectrum can be written as: 
(1.19) 
(1.20) 
For the calculation of more than one component, linear algebra, also known as matrix 
mathematics, is always used. In matrix terms, the equations for two or more 
components can be written in a similar way as the equations above: 
( 1.21) 
where A stands for a (2 x I) matrix of absorbances at two wavelengths, K represents a 
(2 x 2) matrix of the absorptivity constants, C and E are the (2 x 1) matrix of the 
concentrations of the two constituents and absorbance error respectively. 
The employment of a matrix is ideal for chemometrics since the data obtained from 
optical spectrometers often form a large set with every spectrum consisting of 
thousands of wavenumbers. Moreover, matrix mathematics is perfectly suited for 
computers. 
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CLS can be used if the system consists of several components and is relatively robust 
to spectral noise since a large number of wavelengths or wavenumbers can be chosen. 
However, it requires knowledge of all the components in the mixture and also that no 
interactions between the components occur. CLS is therefore often not suitable in 
industrial applications, where various excipients are added in the formulation, and 
knowledge about interactions between the components is often not available. One 
solution to this problem is to rearrange Beer's Law (Equation 1.22) as shown below: 
(1.22) 
where C is the concentration of the constituent; A,i is the spectral response; K;, 
represents the absorptivity constant, which combines the constituent absorptivity 
coefficient constant ( s,.) and pathlength of the light (b ). 
Substituting JI K,i with a constant P, the equation above can be expressed as: 
(1.23) 
In this case, E stands for concentration error, which is the residual error between the 
least squares fit line and the actual constituent concentration. 
This method is called ILS (Inverse Least Squares). Similar to CLS, for the two or 
more components mixtures, matrix mathematics can be used for the calculation in 
ILS. However, the expression above implies that the concentration is a function of the 
absorbance in ILS. This difference provides a main advantage of ILS over CLS, 
which is the concentration of the component of interest can be quantified accurately 
without the knowledge of the other sample constituents or interference in the spectra. 
This enables its potential application for various natural and manufactured products 
which are complex systems. 
Principal components analysis (PCA) and partial least squares (PLS) are two methods 
which are based on the two classic methods described above, but are more robust to 
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errors such as instrument variation, detector noise and changing environmental 
conditions, since two new variables "variation spectra/eigenvectors and scores" are 
introduced into the calculation. Variation spectra/eigenvectors, as the name implies, 
represent the changes in the absorbance of the constituent directly caused by its 
changes in the concentration. The idea behind this is that although complex variations 
make up a spectrum, there should be some finite number of independent variations 
occurring in the spectral data and the largest variations in the calibration set would be 
the changes in the spectrum due to the different concentrations of the constituents in 
the mixture. The finite number is called "scores", which is a scaling constant used to 
reconstruct the spectra since the concentrations of the constituent are all different. In 
PCA, the dimensionality of the multidimensional data is reduced by transforming the 
original variables into new axes which will be laid along the directions of maximum 
variance of the data with the constraint that the axes are orthogonal. The orthogonal 
features are called principal components (PCs). Mathematically, the spectral matrix is 
composed into a set of eigenvectors and scores and then is regressed against 
constituent concentrations. All the parameters in PCA for the new variables are 
linearly combined where the first principal component describes the largest variance 
with normalized coefficients applied to the variables used in the linear combinations, 
the second component has the most remaining variance etc. A detailed description of 
PCA has been provided in several books and tutorials [124-127]. PCA can be used to 
examine observations, structures, similarities and trends of large data sets. In 
pharmaceutics, it has been widely applied in research and development for instance 
for particle characterization [128], process monitoring [129] and formulation 
development [130]. 
PLS is similar to PCA, but besides calculating the PCA eigenvectors and scores, the 
PCA scores are also regressed simultaneously against the constituent concentrations 
using a regression method. In PLS, the resulting spectral vectors can be directly 
related to the constituents of interest and spectra containing higher constituent 
concentrations are weighted more heavily than those with low concentrations. 
Because of the simultaneous calculation of the spectral and concentration data in PLS, 
PLS model equations are significantly more complex than those of PCA and thus 
more difficult to understand and interpret. However, there are several advantages of 
employing PLS for example it is capable of analyzing very complex mixtures since 
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only knowledge of constituents of interest is required [131]. Also, PLS enables 
modeling of data in which the number of variables exceeds the number of 
observations. Furthermore, for analyzing a system consisting of constituents with 
highly varied concentrations, PLS has been reported to almost certainly show good 
prediction [132]. Therefore, PLS modeling has become the most widely utilized 
multivariate technique in the pharmaceutical field especially in quantitative analysis 
of pharmaceutical polymorphs [71, 102, 133-136]. The algorithms for calculating the 
PLS model eigenvectors and scores have been described in detail in several books and 
reviews [122, 123, 131, 137]. 
For the analysis of the spectral data, spectral preprocessing is often a necessary first 
step. The purpose of using these methods separately or combined are ultimately to 
connect the sample property with the resulting signal most directly and as far as 
possible without the influence of the environment. However, care must be taken not to 
remove useful information during preprocessing. Several commonly employed data 
preprocessing methods and their specific application purposes are listed in Table 1-2. 
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Table 1-2 Some commonly used data preprocessing methods prior to multivariate 
analysis ( adapted from [ 131 ]). 
Tool Specific method Purpose Source of error 
Spectral Normalisation Minimum- Removes Sample volume 
preprocessing maximum differences in or thickness 
normalisation, total spectral differences, 
vector normalisation intensity laser intensity 
Smoothing Mean, running Reduces random Noise from 
mean, and running noise over entire emission, 
median smother, spectrum or detection, and 
running polynomial specific spectral sample effects 




Baseline First and second Removes Low frequency 
correction derivatives (running systematic sources of 
dimple and mean differences in variation not 
differences, spectral intensity related to 
Savtizky-Golay), parameters 






Variable Mean Subtraction of mean Removes Some features 
preprocessing centering of the variable intercepts at present in all 





common to all 
samples 
Variable Spectral region Removes Some variables 
weighting selection or redundant data more related to 
weighting or emphasizes instrumentation, 
some variables sample, 
known to be environment 
helpful over effects 
others 
Since both PCA and PLS are methods calculating the principal components based on 
variation spectra and not the absolute absorbance, mean centering is routinely 
performed in multivariate analysis to enhance the subtle differences between the 
spectra. 
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Two other very frequently used preprocessing methods are first derivatization and 
multiplicative scatter correction. The first derivative of spectra is commonly used to 
eliminate baseline offset differences, to reduce scattering effects, and to increase the 
resolution of neighboring peaks so as to facilitate the detection of a small analyte 
peak. Multiplicative scatter correction is a method used for reducing scattering effects 
that arise from particle size or packing differences among samples. Also, standard 
normal variate transformation and orthogonal signal correction which remove 
variation in the spectral data unrelated to the measured values have been shown to be 
useful preprocessing methods by a number of authors [129, 138, 139]. The detailed 
theories behind these preprocessing tools are well explained in several books and 
literature [131, 132, 137]. 
1.5 Carbamazepine and carbamazepine dihydrate 
Carbamazepine (CBZ, dibenz[b,f]azepine-5-carboxamide) was chosen as the model 
drug in this study. The chemical structure of CBZ is shown in Figure 1.13. CBZ has 
attracted intensive interest from investigators in various areas and the main reason for 
this might reside in its limited bioavailability due to its low aqueous solubility. CBZ 
has been used as an important drug for the treatment of epilepsy and trigeminal 
neuralgia for almost 40 years [140-142]. 
(C15H12N20, Mol wt: 236.28) 
Figure 1.13 Chemical structure of CBZ. 
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1.5.1 CBZ polymorphs 
The investigation on CBZ crystalline structures started in the early 1960s when it was 
first found to exist in several polymorphic forms by Kuhnert-Brandstatter. The 
existence of four CBZ anhydrates (forms I, II, III and IV) was suggested in 1968, and 
consequently, characterization on these forms by microscopy was carried out in 1971 
(Kuhnert-Brandstatter, Kofler et al. 1968; Kuhnert-Brandstatter 1971). CBZ 
molecules exist in a dimer structure in all four polymorphs, and the conformation and 
hydrogen bonding scheme remain constant in all the polymorphs. The differences 
between the CBZ polymorphs are solely in the packing of the carboxamide dimer 
units (shown in Figure 1.14). The existence of CBZ in a dimer structure has also 
recently been confirmed by computer modeling [143]. 
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(A) (B) 
(C) (D) 
Figure 1.14 Diagrammatic representation of the hydrogen bonding pattern in CBZ 
polymorphs: form I (triclinic) (A); form II (trigonal) (B); form III (P-monoclinic) (C); 
and form IV (C-monoclinic) (D) (adapted from [144]). 
Himes et al. identified the accurate packing arrangement and conformation of the unit 
cell of one CBZ polymorph in 1981, using single crystal X-ray analysis on a form 
obtained by recrystallization from absolute ethanol [145]. This form was later 
identified to be the most stable form at room temperature and it is the form used in the 
marketed CBZ tablets. The molecular structure of this form (termed form III) is 
shown in Figure 1.15. 
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Figure 1.15 Conformation diagram of CBZ form III (adapted from [145]). 
In 1987, another CBZ polymorph, form II (trigonal), was identified by Lowes et al. 
[146]. These authors obtained form II by recrystallization from a few solvents with 
low dielectric constants such as carbon tetrachloride, tetrahydrofuran, and 
cyclohexane, and again used single crystal X-ray diffraction for analysis. The 
molecular structure of this form (form II) is shown in Figure 1.16. 
Figure 1.16 Conformation diagram of CBZ form II (adapted from [146]). 
The identification of CBZ form I was very complex and its molecular structure was 
only recently clarified by Grzesiak et al. (2003) [144, 147]. 
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R•shlu~.3 
Figure 1.17 Conformation diagram of CBZ form I (adapted from [144]). 
CBZ form IV is the least stable form among four commonly existing CBZ 
polymorphs at room temperature. It was prepared by slow evaporation of a methanol 
solution at room temperature in the presence of hydroxypropyl cellulose. Its single 
crystal characterization was also reported recently (Figure 1.18) [144, 148, 149]. 
Figure 1.18 Conformation diagram of CBZ form IV (adapted from [148]). 
Krahn and Mielck (1987) investigated the stability of CBZ forms I, II and III with 
regard to temperature and a semi-schematic energy/temperature diagram was 
established [150]. 
It can be seen that the conformation of the CBZ molecules in the polymorphic forms 
is quite similar indicating that CBZ is not a flexible molecule. The main differences 
are in the differences of the carboxamide group (see arrows in Figures 1.15 - 1.18). 
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Figure 1.19 Semi-schematic internal energy (E)/temperature diagram for CBZ forms 
I, II and III: G is the free energy, H is the enthalpy of each CBZ form, subscript 1 
denotes the melt; L'lH1,1 and L'lHm,1 stand for the determined enthalpies of fusion of 
form I and of transition of form III to I, respectively (adapted from [150]). 
The melting points of all CBZ forms were obtained from this diagram. They are the 
intersections of the G isobar for the liquid form (G1) with the respective isobars for 
each form (174 °C, 185 °C and 190 °C for forms III, II and I, respectively). The 
thermodynamic transition points between every two pairs of the three forms (forms I 
and II, forms II and III, and forms I and III) (indicated by the crossings between each 
two lines (G1 and Gn, Gu and Gm, and G1 and Gm) were lower than the melting point 
of the lower melting form correspondingly in the comparison. Therefore, according to 
the definition of the heat of transition rule described above, all three CBZ forms are 
enantiotropic with respect to each other. This relationship between CBZ forms has 






Chapter 1 Introduction 
1.5.2 CBZ dihydrate (DH) 
The CBZ molecule can hydrogen bond to two water molecules forming a dihydrate 
(DH). One water molecule interacts with the carboxyl group of CBZ and the other 
with the amino group (Figure 1.20) [151] . It was found that CBZ also exists as a 
dimer in the DH form (Figure 1.21) [152]. 
0-H""""' o-r:. 
~ , --,~H'""'" ?,-H 
H H 
(Cl5Hl2N20•2H20, Mol wt: 272.28) 
Figure 1.20 Chemjcal structure of one DH molecule [151]. 
Figure 1.21 DH crystal lattice structure viewed down the b-axis (adapted from [152]). 
The crystal structure and unit cell parameters of DH were reported by Dugue et al. 
[153] , where the c-cell shows a much higher value (28.70 A) than a and b-cells (19.73 
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of CBZ) explaining at least in part that a needle-like morphology of the DH crystals 
(shown in Figure 1.22). 
Figure 1.22 SEM micrograph showing the morphology of typical DH crystals. 
Heterogeneous nucleation of DH on the surface of CBZ form III has been found by 
Lowes early in 1980s [146], and the conditions (solid phase composition and 
supersaturation) under which this crystaJlization occurs have been recently identified 
[151, 154] [152]. 
As described above (Section 1.2.4.2), hydrates can be divided into three main classes 
according to their internal structure, DH has been grouped into Class 2 (channel 
hydrates). This means the water molecules in the DH lie next to other water molecules 
of adjoining unit ceJls along an axis of the lattice, forming "channels" through the 
crystal. For the dehydration of the DH, an interesting phenomenon of channel 
hydrates can be observed. Under the light microscope, it can be seen that the 
dehydration of DH begins at ends of the needle-like crystal and continues toward the 
center along the channels inside the crystal. This can be seen as a progressive 
darkening from the ends of the crystal to the center along the longest crystaJJographic 
axis [2, 3]. 
DH is the most stable form of CBZ in aqueous suspension and is the form present in 
the commercial CBZ suspension Tegretol®. However, DH has also been found as 
impurity in the marketed CBZ tablets particularly in those tablets stored in the 
presence of moisture [155, 156]. The presence of DH was considered to be the main 
cause for therapeutic failures of marketed CBZ tablets and resulted in a recaJJ of CBZ 
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[157, 158]. The detailed information of CBZ forms and literature reports for CBZ and 
its formulation are further discussed in the introduction sections of each of the 
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1.6 Project aims 
The investigation of pharmaceutical substances and formulations in an aqueous 
environment is still at a very early stage; this however, is at least partially due to the 
widely acknowledged difficulties in applying solid state techniques such as XRPD, 
DSC and FT-IR in an aqueous environment. Although several recent studies have 
demonstrated the potential of employing Raman spectroscopy in studying such water 
related systems, its applicability (both off-line and in-line) in monitoring polymorphic 
conversions in aqueous suspension is still unknown. 
CBZ was chosen as a model drug in this study, since in addition to its ideal character 
for solid state studies mentioned above, it also has a strong Raman signal which 
facilitates its detection especially when water is present as a diluent. 
Therefore, the main aims of this study are: 
1. to gain an insight into the polymorphic conversion of CBZ to DH in aqueous 
suspension in the presence and absence of excipients, 
2. to develop a useful and reliable method for applying Raman spectroscopy in 
characterizing polymorphic conversion of CBZ to DH in aqueous suspension, 
3. to investigate the influence of internal structure (polymorphs), external shape 
(morphology) and excipient interaction on the conversion kinetics of CBZ in 
aqueous suspension and also on the in vitro dissolution performance of CBZ. 
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2.1 Materials 
2.1.1 Carbamazepine forms 
Carbamazepine (CBZ) form III (Alphapharm Pty Ltd, Glebe, Australia) was used as 
received. 
CBZ form I was prepared by heating the source material at 150 °C for 3 h as 
described by Grzesiak et al. [144). Two source materials were used for form I 
preparation: form I (1'1 batch) from Sigma Chemical Company (St. Louis, MO) and 
form I (2nd batch) from Sigma-Aldrich Chemie (Munich, Germany). 
Form II was prepared by freeze-drying fresh DH. DH was prepared from the CBZ as 
received from Sigma Chemical Company (St. Louise, MO) by recrystallization from 
an ethanol-water mixture as reported by Krahn and Mielck [150). All forms were 
confirmed by X-ray powder diffraction as reported previously [144, 150]. 
2.2 Methods 
2.2.1 X-ray powder diffraction (XRPD) 
The XRPD measurements were performed using a Philips PW 1130/00 X-ray 
generator (Philips, Almelo, The Netherlands), and a Phililps PW 1050 goniometer 
(Philips, Almelo, The Netherlands). The X-ray generator was set to an acceleration 
voltage of 40 kV and a filament emission of 20 mA. All measurements were recorded 
at room temperature. The diffraction patterns were collected over the range of 8 - 40° 
(2e) at a step size of 0.02°(28) using an aluminium sample holder. The diffractograms 
were displayed using Mac Diff version 4.0.5 software (A. J. Hall, Applied Geology, 
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2.2.2 Raman spectroscopy 
The FT-Raman instrument consisted of a Bruker FRA 106/S FT-Raman accessory 
(Bruker Optik, Ettlingen, Germany) with a Coherent Compass 1064-500N laser 
(Coherent Inc, Santa Clara, USA) attached to a Bruker IFS 55 FT-IR interferometer, 
and a D 425 Ge diode detector. Analysis was carried out at room temperature utilizing 
a laser wavelength of 1064 nm (Nd:YAG laser) and a laser power of 105 mW. Back-
scattered radiation was collected at an angle of 180°. Samples were packed into an 
aluminum cup and a total of 16 scans was averaged for each sample at a resolution of 
4 cm- 1• Sulphur was used as reference standard to monitor the wavenumber accuracy. 
OPUSTM 5.0 (Bruker Optik, Ettlingen, Germany) was used for all spectral analysis. 
2.2.3 Raman microscopy 
FT-Raman mjcroscopy (Ramanscope II Bruker Optik, Ettlingen, Germany) was also 
used for qualitatively determjning the changes of the crystal during hydrate formation. 
The optical and Raman images were obtained using a 40 x objective, and Raman 
spectra were acquired using 16 scans at a laser power of 500 mW. There was no 
visual sign of physical or chemical changes after irradiation. Data collection, stage 
control and data processing were preformed using software OPUSTM 5.5 (Bruker 
Optik, Ettlingen, Germany). 
2.2.4 Differential Scanning Calorimetry (DSC) 
Thermal analyses of the different CBZ forms and the recovered samples were 
performed using a DSC - QlOO (TA instruments, New Castle, USA). Samples were 
weighed into aluminum pans without a pinhole and sealed with a crimper. The 
thermal behavior of the samples was studied under a dry nitrogen purge (20 ml/min) 
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2.2.5 Thermogravimetric analysis (TGA) 
The weight loss of the compact sample recovered after exposure to water for 4320 
min was measured using a TGA - Q 50 (TA instruments, New Castle, USA). Approx . 
5 mg of the sample was evenly distributed onto the platinum sample pan. The 
sampling was carried out in triplicate. The heating range used was from 25 to 210 °C 
at a heating rate of 10 °C/min using dry nitrogen as a purge gas. The total volatile 
yield was calculated from the mass loss in the TGA - Q50. 
2.2.6 Scanning electron microscopy (SEM) 
SEM (Cambridge Instrument, Stereoscan 360) was performed using a 15 kV beam 
acceleration voltage. Micrographs were recorded using a PGTE Mitsubishi 
video/copy processor. Samples were mounted onto a strip of double-sided carbon tape 
and sputter coated with a thin layer of gold-palladium under argon vacuum prior to 
analysis. 
2.2.7 Multivariate analysis 
Multivariate analysis on the Raman spectra obtained was performed using the Quant2 
package that accompanies OPUS™ software (Bruker Optics, Germany). The selection 
of spectral regions for calibration was based on the wavenumber regions that showed 
the largest differences between the components and therefore provided the greatest 
contribution to the linear regression equation for the analyte. All spectra were mean 
centered. Although every effort was made to pack the sample cups consistently, 
multiplicative scattering correction (MSC) was applied to correct spectra intensity 
differences due to packing differences. Other spectral preprocessing consisted of first 
derivative calculation if necessary to remove baseline differences. The calibration 
models were calculated using the PLS algorithm and cross-validation (one sample 
removed per cycle). The root-mean-squared errors of cross validation (RMSECV) 
were determined for each number of factors. The number of factors used to construct 
the models was based on the lowest RMSECV without exceeding three factors for the 
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Chapter 3 
Deeper understanding of the phase transformation of carbamazepine 
polymorphs in aqueous suspension using Raman spectroscopy 
combined with multivariate analysis* 
' The work presented in this chapter has been previously published in the Journal of Pharmaceutical 
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3.1 Introduction 
Polymorphic phase transformations can lead to changes m processability, 
bioavailability and stability of drugs [159]. These properties can change as a result of 
polymorphic interconversions , desolvation of solvates, alteration of the crystallinity or 
formation of hydrates. Solvent mediated polymorphic transformations from the 
anhydrate to the hydrate form of the drug are likely to be induced in certain 
pharmaceutical manufacturing processes, e.g. wet granulation [71]. Also recent 
studies with various drug compounds have shown the influence of polymorphic 
conversions during dissolution testing of tablets [70, 160]. 
The control of the polymorphic form is obviously vital in drug development. For this 
purpose, various solid state characterization techniques are required to generate 
meaningful supporting data. Amongst a wide range of analytical techniques, Raman 
spectroscopy has attracted growing attention recently, and has been widely used in 
identifying and characterizing polymorphs [25 , 161-164]. There are several 
advantages of using FT-Raman spectroscopy as an analytical tool. Firstly, almost no 
sample preparation is required which facilitates quantitative analysis in polymorphic 
mixtures and formulations since polymorphic changes or spectral variances due to 
sample preparation are limited [165-168]. Secondly, slurry samples can be measured 
directly since water has a very weak Raman spectrum, in contrast to infrared 
spectroscopy where water shows a high absorption. This advantage of Raman 
spectroscopy has been successfully employed in the investigations of emulsion and 
suspension formulations [169, 170], including the quantitative analysis of the 
polymorphic conversion of theophylline [171], L-glutamic acid [172] , progesterone 
[173], MK-A [135] , D-mannitol [174] , and the hydrate formation of theophylline and 
caffeine [71]. Thirdly, the small sample size required combined with the non-invasive 
measurements all contribute to its great potential for application in pharmaceutical 
research and industry [78, 175-177]. 
Data analysis is the key for improved understanding of any produced data in drug 
development. Lately the pharmaceutical industry has been encouraged to apply 
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systems consequently providing minimized risks for failures [ 178]. In these cases the 
collected data will most often be multidimensional in nature and multivariate data 
analysis tools become useful in data interpretation and modeling. Partial least squares 
(PLS) modeling has recently received considerable attention in quantitative 
spectroscopy. The combination of multivariate analysis with Raman spectroscopy has 
demonstrated a greatly increased ability in achieving precise quantification of various 
pharmaceutical systems [71 , 133-136, 161, 164]. 
Carbamazepine (CBZ), an important anti -convulsant drug for epilepsy and trigeminal 
neuralgia treatment [ 179], has been known to be very unstable when exposed to 
moisture and converts rapidly to its dihydrate (DH) when exposed to water. It has also 
been found that DH has the slowest dissolution rate and solubility (approximately two 
thirds of that of CBZ form III) [ 180], the conversion to the DH reduced the 
dissolution rate and solubility of the drug and led to a great decrease in the 
bioavailability of its marketed tablets [155, 157]. 
There have been a number of studies focusing on the transformation of CBZ form III 
to the DH in the past 20 years. Quantification of the relative amounts of CBZ form III 
and DH in a mixture by XRPD was carried out by Suryanarayanan [120], who 
subsequently reported first order kinetics of transformation from form III to the DH 
by quantifying the relative peak intensity changes of X-ray powder diffraction 
(XRPD) during the conversion [181]. Recently, Brittain [182] reported a novel way of 
characterizing the transformation kinetics of form III to the DH by detecting the 
fluorescence changes during the conversion since the polymorph and the DH show 
substantial fluorescence differences. However, with the exception of fluorescence 
detection, techniques used for quantifying CBZ conversion to the DH thus far have 
only been XRPD, differential scanning calorimetry and Karl-Fischer titration, which 
are time consuming, and most importantly, polymorphic changes can potentially be 
induced during sample preparations such as filtration, grinding and drying. 
In this chapter, the conversion kinetics of three CBZ polymorphs - forms I, II, III 
separately, and also a mixture of forms I and III to the DH in aqueous suspension 
were investigated using Raman spectroscopy. PLS was applied in analysing the 
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aim of this chapter is to gain a greater insight into the transformation kinetics of the 
different CBZ polymorphs during dispersion. 
3.2 Materials and Methods 
3.2.1 Materials 
CBZ forms were supplied and prepared as specified in Section 2.1.1. The particle size 
of the different polymorphic CBZ forms was controlled by sieving them to the range 
180 to 250 µm (Test sieves, Endecotts Ltd, England). 
3.2.2 Measurements 
3.2.2.1. X-ray powder diffraction (XRPD) 
XRPD analysis was used to confirm the nature of prepared CBZ polymorphs and also 
to characterize the recovered samples after dispersion in water for 210 min. The 
dispersed CBZ were recovered by pouring the whole dispersion onto three layers of 
filtration paper. The resulting slurry on the filtration paper surface was scraped off 
with a spatula, and then transferred into three aluminum sample holders 
consecutively. The XRPD measurements were carried out immediately after filling 
the sample holders. The detailed XPRD method was specified in Section 2.2.1. 
3.2.2.2. Scanning electron microscopy (SEM) 
SEM micrographs were taken using the method specified in Section 2.2.6. 
3.2.2.3. Raman spectroscopy 
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3.2.3 Mixture quantitation 
3.2.3.1. Binary model prepared from recovered slurries 
Binary mixtures of CBZ form I (1st batch) and DH, and form II and DH were 
prepared separately in triplicate at 20 % (w/w) intervals from Oto 100 % form I (form 
II) in DH (20 mg per sample). Each powder mixture was transferred into a 2 ml glass 
tube and a small magnetic stirrer was added. Immediately after adding 1 ml distilled 
water, the tube was capped, shaken up and down once and put into a water jacketed 
beaker. Each sample was stirred for 10 s using a magnetic stirring plate (Telemodul 
40S, Alphapharm), and then recovered by pouring the dispersion onto two layers of 
filtration paper to remove excess water. The CBZ slurry on the filtration paper surface 
was scraped off with a spatula, and was then transferred into three aluminium sample 
cups consecutively (about 1 mg sample per cup). The Raman spectra were recorded 
immediately after filling the sample cups. 
As CBZ is only very slightly soluble in water at room temperature [183] it was 
assumed that the dissolution of CBZ had no influence on its solid dispersion 
concentration. Also, in order to confirm that there was no change in the DH during 
dispersion, pure DH was dispersed in water for 210 min and then recovered for 
analysis as described above. 
3.2.3.2. Binary models prepared from dry powder 
Using geometric m1X1ng, CBZ polymorphs of forms I (1 st batch), II and III were 
blended separately with DH in a mortar and pestle (with minimum grinding) to form 
binary physical mixtures at 20 % (w/w) intervals from O to 100 % CBZ anhydrate in 
DH (20 mg per sample). Each concentration was prepared in triplicate and measured 
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3.2.3.3. Ternary model prepared from dry powder 
Thirty-three ternary mixtures (100 mg per mixture) of form I (2nd batch), form III and 
DH were prepared as an independent sample set for the ternary model. The 
concentrations of each component were randomly varied based on the experimental 
design from OPUS™ software (Bruker Optics, Germany). Each mixture was prepared 
using a mortar and pestle (with minimum grinding) and then measured by Raman 
spectroscopy. 
3.2.3.4. Multi variate analysis 
Multivariate evaluation was performed on the recorded spectral data using the method 
specific in Section 2.2.7. 
3.2.4 Kinetics studies 
Each pure polymorph - forms I (1 st and 2nd batch), II and III was weighed ( 40 mg per 
sample) into a 2 ml glass tube. For the mixture of forms I (2nd batch) and III, 20 mg of 
each form was weighed and then poured together into a 2 ml glass tube (40 mg per 
mixture). All samples were prepared in triplicate. After adding a small magnetic 
stirrer into each tube, water (2 ml) was added and then the stoppered tube was placed 
into 100 ml water jacketed beakers. The dispersion temperature was controlled at 23 ± 
1 °C by using a cooling water bath (Hetofridge, Heto Bire!Z)d, Denmark) and pumping 
the water through the jacketed beakers (VFP, Grant Instrument Ltd, England). 
Independent samples were dispersed for each of the time intervals of 10, 30, 60, 90, 
120, 180 and 210 min, and were recovered for measurement using the same method as 
for the slurry model. 
The differences of the conversion kinetics between polymorphic forms were tested by 
one-way analysis of variance (ANOVA) and Tukey' s pairwise comparisons 
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3.3 Results and Discussion 
3.3.1 Characterization of the initial CBZ polymorphs 
3.3.1.1 . XRPD 
The X-ray diffractograms of each CBZ polymorph (Figure 3.1) agreed well with those 
reported in the literature [144, 150]. However, the relative height of some peaks was 
different between the two batches of form I, which may be caused by different crystal 
habits. As shown by SEM (Figure 3.2), form I (151 batch) consisted of needle like 
crystals, therefore, preferred orientation was likely to be induced when it was packed 
in the XRPD sample holder. 
Form I (2nd batch) 
Form I (1st batch) 
10 15 20 25 30 35 40 
Diffraction Angle (28] 
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3.3.1.2. SEM 
The morphology of all CBZ polymorphs - form I (1st and 2nd batch), II and III which 
were used for the kinetics studies is shown in Figure 3.2 . 
Figure 3.2 SEM micrographs of CBZ polymorphs: A) form I (1st batch); B) form I 
(2nd batch); C) form II; D) form III (horizontal scale bars: 1.00 mm). 
As mentioned above, the characteristic peak positions in the X-ray diffractograms of 
the two batches of form I agreed well with each other although some relative peak 
heights differed. However, their morphology was obviously different. Form I (1st 
batch) consisted mainly of prism like particles (Figure 3.2A), while form I (2nd batch) 
consisted of needle like aggregates (Figure 3.2B). Form II also exhibited a needle like 
morphology but the needles appeared more densely packed than the form I needles 
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3.3.1.3. Raman spectroscopy 
Raman spectra for the initial CBZ polymorphic forms are shown in Figure 3.3. There 
were many spectral differences between these polymorphs (indicated by the arrows). 
Since crystal shape has much less influence on the Raman spectrum than on the X-ray 
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Figure 3.3 Raman spectra of the initial CBZ polymorphs. (Arrows show area of 
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Characterization of the samples recovered after 210 min dispersion in 
aqueous suspension 
3.3.2.1 . XRPD 
The diffractograms for the recovered samples from 210 min dispersions the pure 
forms I, II, III and the mixture of forms III and I dispersed in water are shown in 
Figure 3.4. The DH has characteristic peaks at 8.9, 12.1 and 18.7° (28) which could be 
found in the diffractograms of all the recovered samples. Also, characteristic peaks for 
each polymorph remaining in the recovered samples could be seen (indicated by the 
arrows in Figure 3.4). The diffractogram of the recovered form I (2°ct batch) was very 












Figure 3.4 X-ray diffractograms of the recovered (rec) forms and the dihydrate (DH). 
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3.3.2.2. SEM 
The morphology of the recovered samples from 210 mm dispersion of each pure 
polymorph and also of the forms I and III mixture are shown in Figure 3.5. A distinct 
and common feature seen in Figure 3.5A, C and D was some areas of closely packed, 
smooth surfaces. However, this feature was absent in Figure 3.5B, where almost all 
crystals were of needle like shape (typical DH morphology) [ 154, 163, 184]. This 
confirmed the finding from XRPD that form I (2nd batch) converted mostly to the DH 
after 210 min dispersion, while the other polymorphs - forms I (1 st batch) , II and III -
still had a certain amount of original crystals remaining in the suspension. 
Figure 3.5 SEM micrographs of the recovered forms: A) form I (1 st batch); B) form I 
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3.3.2.3. Raman spectroscopy 
Raman spectra for all the recovered samples showed different peak patterns to their 
initial polymorphs and also an increased similarity to that of the DH, especially for 
the recovered form I (2nd batch). Although Raman spectra for the two batches of form 
I were exactly the same (Figure 3.3), differences can be seen in the spectra (around 
3050, 1000, 800 and 400 cm- 1) of the recovered samples due to different extents of 
conversion. The spectrum of the slmTy recovered from the pure DH dispersion is also 
shown in Figure 3.6, and is identical to the DH spectrum. The Raman spectrum for the 
recovered sample after dispersing DH in water for 210 min is also shown in Figure 
3.6. It is identical to the DH spectrum, confirming that there is no change in the DH 
during dispersion. 
3100 3000 1600 1400 1200 1000 800 600 400 200 
Wavenumber [cm-1] 
Figure 3.6 Raman spectra of DH and the recovered (rec) CBZ samples . 
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3.3.3 Conversion kinetics 
3.3.3.1. Quantitation of the binary mixtures 
Table 3-1 shows the parameters used for the quantitative models of all binary 
mixtures. As well as MSC, all the spectra were converted to their first derivatives. For 
all models, the RMSECV was less than 8 % suggesting a good predictive ability of 
the models. The lower RMSECV for the slurry model is probably due to better 
mixing. However, as described in the next section, slurry models are prone to 
polymorphic conversion due to the presence of the water in their preparation, which 
can affect the model accuracy. 
Table 3-1 Parameters used in the generation of the binary models and model 
assessment. 
Model Recovered slurries Dry powder 
Mixture Form I (I" Form II/DH Form I(]" Form II/DH FormIIUDH 
batch)/DH batch)/DH 
1514.3 - 1473.8 3099.7 - 3003.3 1514.3 - 1473.8 3236.7 - 2849.0 1685.9- 1473.8 
Spectral regions 1282.8 - 1234.6 1722.6 - 1390.8 1282.8 - 1234.6 1682.1 - 1469.9 1269.3 - 1099.6 
(cm-I) 1147.8 - 1082.2 1277.0-1080.3 1147.8 - 1082.2 1433.3 - 1388.9 740.8 - 706.1 
1061.0 - 1008.2 906.7 - 733.1 1061.0 - 1008.2 1273.2 - 1234.6 640.5 - 557.6 
818.0- 760.1 661.7 - 603.9 818.0- 760.1 1176.7 - 1093.8 405.2 - 349.3 
630.9 - 609 .5 351.2 - 308.8 630.9 - 609.5 899.0 - 862.3 
596.2 - 528.6 596.2 - 528.6 740.8 - 519.0 
596.2 - 528.6 596.2 - 528.6 499.7 - 430.3 
347.3 - 308.8 
Factors used 3 2 2 2 2 
RMSECV(%) 1.70 3.12 4.56 5.39 7.71 
R" 0.998 0.991 0.982 0.975 0.952 
Furthermore, as particle size has been reported to influence peak intensity and/or 
width which can result in errors in the calibration model based on the relative 
intensity and/or width changes of some peaks [174, 185, 186], form III of different 
size ranges was measured by Raman spectroscopy. The spectral variances induced by 
differences in particle size and packing were small and became negligible after 
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processing (MSC and first derivative calculation) for PLS analysis. Furthermore, the 
ability of applying PLS to correct particle size effects on the relative peak intensities 
in Raman spectra for quantitative analysis of polymorphic forms has been reported by 
Zhou et al. in 2002 [76]. 
3.3.3.2. Conversion kinetics of the pure CBZ polymorphic forms 
As shown above, two methods were used for the model preparation of form I -
recovered slurries and dry powder. Therefore, conversion kinetics based on the two 
types of binary models were plotted together for form I (Figure 3.7) in order to 
compare differences between these two models. An assumption was made that each 
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Figure 3.7 Conversion of form I based on the two types of binary calibration models: 
form I (1st batch) based on model from (•) dry powder and (o) recovered slun-ies; 
form I (2°d batch) based on model from (A) dry powder and (Ll) recovered slurries. 
Values based on the model from dry powder are interpolated by the solid lines; values 
based on the model from recovered slurries are interpolated by the dotted lines. 
67 
Chapter 3 Phase transformation kinetics of carbamazepine 
For each batch of form I, the slmTy and powder models agreed very well with each 
other, confirming the applicability of both models when using them for kinetics 
studies. However, for the model using the recovered slurries to be accurate, it is 
necessary that no polymorph converts to the DH during the dispersion of the 
polymorph in water, which may not be the case for very fast converting samples, such 
as form II. Although the conversion trends of form II predicted by the two models 
were similar, the actual values of the DH formation predicted from the slurry model 
were about 20% less than those for the powder model (Figure 3.8). This difference 
was due to conversion to the DH in the 10 s dispersion preparation. Since calibration 
models using dry powder mixtures to quantify polymorphic conversion in aqueous 
suspension were found to be accurate by Ono et al. [ 172] using both off-line and in-
situ measurements, quantitative models using dry powder mixtures were prepared for 
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Figure 3.8 Conversion of form II based on the two types of binary calibration models: 
from(•) dry powder and (o) recovered slurries. Values based on the model from dry 
powder are interpolated by the solid lines; values based on the model from recovered 
slurries are interpolated by the dotted lines. 
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As first order kinetics have been reported for the conversion of CBZ form III to the 
DH in aqueous solution by a few authors [181, 182], the same kinetics were evaluated 
for the conversion of all CBZ forms. Figure 3.9 shows conversion profiles for all 
these forms using their corresponding binary quantitative models, and first order 
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Figure 3.9 Conversion of CBZ polymorphs as predicted by the binary models: (A.) 
form I (1st batch); (111) form III;(•) form II; (T) form I (2nd batch). 
Table 3-2 shows the calculated rate constants ( k) and the unconverted portions ( B) 
after 210 min dispersion in aqueous suspension (t = time). 
y = B+Ae-kr (3.1) 
Table 3-2 First-order rate constants and unconverted portions after 210 min 
dispersion in aqueous suspension for each CBZ form. 
Crystal habit Prism like crystals Needle like crystals 
CEZ forms Form I (1 ") Form III Form I (2"a) Form II 
Rate constant (min-1) 0.0196 ± 0.0037 0.0529 ± 0.0134 0.0982 ± 0.0182 0.174 ± 0.021 
Unconverted portion 
(%) 
34.6 ±3.8 51.1 ± 1.4 16.5 ± 1.9 27.9 ± 0.4 
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Furthermore, the incomplete conversion for the recovered samples after 210 min 
dispersion in water was supported by results obtained using SEM, XRPD and Raman 
spectroscopy. This incomplete conversion might be caused by the DH needles 
forming at the surface of the particles and then covering the surface of the remaining 
anhydrate, thus slowing down or even stopping fmther conversion. 
Other possible kinetic models based on solid-state reaction mechanisms were also 
considered [187-189] (Table 3-3a). The fitting efficiency for all the models was 
evaluated by using the coefficient of determination (R2) (Table 3-3b). 
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Table 3-3 Kinetic models fitted for the conversion profiles of all CBZ forms. 












M113 = M t3 -kt 
Mechanism 
First order mechanism with an 
unconverted portion 
Exponential two phase decay 
Two-dimensional growth of nuclei 
mechanism (Avrami equation) [187-189] 
Three-dimensional growth of nuclei 
mechanism (Avrami equation) [187, 189] 
Dissolution of monodispersed powder 
under sink conditions (Hixon-Crowell 
equation) [190] 
Table 3-3 (b) Correlation coefficients (R2) of the fitted mechanisms for all CBZ 
forms. 
Equations Form I (1st batch) Form I (2" batch) Form II Form III 
0.960 (81) 0.965 (81) 0.973 (81) 0.949 (8 1) 
Ml 0.988 (61) 0.982 (41) 0.999 (41) 0.956 (61) 
M2 0.960 (81) 0.983 (81) 0.999 (81) 0.949 (8 1) 
0.893 (6 ) 0.661 (5) Bad fit 0.626 (6) 
M3 0.977 (5 12) 0.767 (412) 0.952 (612) 0.908 (5 12) 
0.769 (6) 0.568 (5) Bad fit 0.552 (6) 
M4 0.973 (5 12) 0.773 (412) 0.951 (612) 0.917 (5 12) 
MS 0.984 (61) 0.902 (41) 0.490 (61) 0.844 (5 1) 
1Number of data points used in analysis shown in parentheses after R2 value 
2Zero point was omitted 
The best fitting and simplest model was a first order kinetics model (M 1) with an 
unconverted portion (R2 2: 0.949). However, the form II kinetics appeared to be best 
described by a two phase model (M 2) consisting of a very fast initial conversion 
followed by a sustained slow conversion (R2 = 0.999). This fast initial conversion 
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may be related to voids in the form II crystal structure, which greatly facilitated the 
penetration of water into its crystals [146]. 
Further samples would have been desirable in the early phase for the rapidly 
converting forms. However, this was limited due to the off-line nature of the 
measurement where high variances were likely to be induced by sampling errors in 
the fast converting phase. 
One-way ANOV A was used to test if there were significant differences in the 
conversion kinetics between the crystals of similar shape but different polymorphic 
form. There was no significant difference between form I (1st batch) and form III 
prisms. 
Also, for form I (2nd batch) and form II needles, no significant differences were 
detected at every conversion time point except 60 and 90 min. The similar conversion 
rates may be due to Form II and I needles having very similar hydrogen bonding in 
their crystal structures [144]. Also, form I (2nd batch) consisted of aggregated needles 
(Figure 3.2), which might be deaggregated, thus increasing the exposed surface area 
which explains its highest conversion extent among all the forms (almost of 90% 
conversion at 210 min). 
However, the conversion profiles of the two batches of form I with different crystal 
morphology were significantly different. The needle like form I (2nd batch) had a 
higher conversion rate (about 5 times faster) and conversion extent (about 30% more 
converted to the DH after 210 min dispersion). 
It can be concluded that for samples of the same sieve-size fraction, crystal 
morphology has a greater effect than the polymorphic form on the conversion kinetics 
of CBZ to the DH in aqueous suspension. Since the conversion of CBZ anhydrates to 
the DH are solution mediated [154], surface area may be a critical parameter to 
explain the different conversion profiles between these CBZ forms. The actual surface 
area for these samples was not determined due to the limited amounts of samples 
available in this study, however, from SEM micrographs, the surface area could be 
estimated to be ranked as D <AIC < B (Figure 3.2). 
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The first order rate constant calculated for form III conversion agreed well with that 
repo1ted by Yong and Suryanarayanan [181], confirming the applicability of this 
method for the kinetics studies. However, there was a difference in the extent of 
conversion where form III reached a plateau of 49 % conversion to the DH in this 
experiment but converted completely within 60 min in the study reported in the 
literature. This may be explained by the available surface area for the continuing 
nucleation being limited by the attachment of the DH crystals to the unchanged 
anhydrate. Mechanical agitation may facilitate the removal of these crystals and thus 
allow further conversion. The stirring system used in this study was of much lower 
force than that used by Yong and Suryanarayanan and it was observed under SEM 
that DH needles were attached to or covered the surface of the CBZ samples 
recovered after 210 min dispersion. However, as the particle size range and the 
morphology of the samples used by Yong and Suryanarayanan were not specified in 
their paper, the different extents of conversion might also be due to paiticle 
morphology and size differences between the initial samples. 
3.3.3.3. Quantitation of the ternary, mixtures 
Table 3-4 shows the parameters used in the quantitative ternary model and its 
assessment. Spectra for these models were preprocessed using MSC. The model 
generated a RMSECV of 3 % or less for all components which suggested a very good 
predictive ability of the model. 
Table 3-4 Parameters used in the generation of the ternary model and model 
assessment. 
Component Form III Form I (2n° batch) DH 
Spectral regions (cm·1) 3188.5 - 2887.6; 1529.7- 1469.9; 1446.7 - 991.5; 922.1- 353.1 cm·' 
Factors used 2 4 3 
RMSECV (%) 2.84 2.39 3.00 
RL 0.982 0.990 0.990 
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3.3.3.4. Conversion kinetics of the mixture of forms I (2"d batch) and Ill (50:50) 
The kinetics values of forms I and III from the ternary model were plotted together 
with the halved values based on the binary models (Figure 3.10), since the sample 
concentration of forms I and III in the mixture was half that in their separate 
dispersions. Equation 3.1 was fitted for forms I and III respectively and their first-
order rate constants and the unconverted portions based on the binary and ternary 
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Figure 3.10 Conversion of forms III and I predicted by binary and ternary models: 
form III based on (1111) ternary and (o) binary models; form I based on (A) ternary and 
(il) binary models. Values from the ternary models are shown as solid lines; values 
from the binary models are shown as dotted lines. 
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Table 3-5 First-order rate constant and unconverted portion for forms III and I (2nd 
batch) based on both binary and ternary models. 
CBZforms 
Form I (2"a batch) 
Form III 
First-order rate constant (min· ) Unconverted portion(%) 
Binary models Ternary model Binary models Ternary model 
0.098 ± 0.018 0.147±0.025 34.6±3.8 0.010 ± 0.300 
0.053 ± 0.013 0.023 ± 0.018 51.1 ± 1.4 23.8 ± 6.4 
One-way ANOV A showed that there was no significant difference between the 
conversion rates for form III alone (using the binary model) and form III in the 
mixture (using the ternary model) except for the values at 10 min, although the rate 
constants and the unconverted p01tion were slightly differently predicted by two 
models (Table 3-5). 
For form I, there were significant differences between values at every time point 
except 60 min. Although this difference needs to be investigated fmther, it may be 
due to the small amount of form I remaining in the dispersion and the small 
proportion of the recovered sample measured (of each 40 mg dispersed sample, three 
samples each of about 1 mg were measured after recovery). Furthermore, as shown by 
XRPD (Figure 3.4), some characteristic peaks of form I can still be seen in the 
recovered samples from the mixture of forms III and I after dispersing for 210 min, 
albeit small. 
It may be concluded that there was no interaction or influence on form III conversion 
when dispersed together with form I as the conversion kinetics of form III were 
almost the same as for the pure form III dispersion. The conversion kinetics of form I 
in the mixture were not clearly detected. In a future study, a Raman probe will be used 
to investigate these polymorphic systems, where the sampling errors will be 
minimized and the feasibility of on-line accurate quantitative analysis of these 
polymorphic forms and conversion processes in suspension will be investigated. The 
paiticle size influence of both the anhydrate and the DH on the measurements will 
also be further investigated. 
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3.4 Chapter summary 
The cmTent study has shown that Raman spectroscopy and multivariate analysis can 
in principle be used to characterize and quantify conversions of CBZ polymorphs to 
the DH in aqueous suspension. Also, the crystal morphology rather than the 
polymorphic form of CBZ was found to have more effect on the conversion kinetics, 
indicating the importance of smface properties of crystals to the solution mediated 
conversion. Further investigations on the influence of crystal smface properties and 
morphology changes of CBZ on the hydrate formation process during dispersion in 
aqueous suspension were also carried out and the data will be presented in Chapter 5. 
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Chapter 4 
Effects of excipients on the conversion of carbamazepine to the 
dihydrate in aqueous suspension* 
* The work presented in this chapter has been accepted for publication in the Journal of Pharmacy and 
Pharmacology, 2006. 
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4.1 Introduction 
Carbamazepine (CBZ) is an important anti-convulsant drug [179], of which the 
bioavailability is limited by low water solubility (0.11 mg/ml) although having a high 
intestinal permeability. It therefore belongs to Class 2 of the biopharmaceutical 
classification system (BCS) [191, 192]. 
Efforts have been focused on improving the solubility and dissolution of CBZ form 
III using various excipients and formulation methods [193-201], where the formation 
of CBZ form I or the amorphous form was induced due to its interaction with 
excipients such as PEG and PVP during preparation. However, all these studies were 
carried out in the solid state, and much less attention has been given to the conversion 
of CBZ in aqueous suspension in the presence of excipients. 
Recently, it has been found that the conversion of CBZ to the DH was facilitated 
when CBZ was dissolved in solutions containing various surfactants such as sodium 
lauryl sulfate (SLS) and sodium taurocholate (STC) [152]. This was explained by the 
enhanced dissolution of CBZ in the presence of these surfactants. CBZ solubility was 
also markedly increased in various nonionic surfactants such as Tweens, Myrjs and 
Brijs [202];[191]. Hydroxypropyl methylcellulose (HPMC) and egg albumin, on the 
other hand, have been reported to inhibit the conversion of CBZ to the DH in aqueous 
suspension, with HPMC showing a much higher inhibition ability than egg albumin 
[87, 203]. This group suggested that the strong inhibition ability of HPMC was due to 
structural complementarity between HPMC and CBZ. The bond spacing distance 
(3.69 A) between the oxygen and hydrogen atoms in the CBZ dimer (indicated by* in 
Figure 3 .1, CBZ dimer) was similar to the distance between the oxygen and the 
hydrogen atoms in the cellulose ring of HPMC (indicated by # in Figure 3 .1, 
cellulose) [204]. 
The fact that there are only a few studies of the effect of excipients on the conversion 
of polymorphs of CBZ to the dihydrate may be a consequence of the difficulties in 
studying such compounds in an aqueous suspension using standard solid state 
techniques such as XRPD. However, it has been shown in Chapter 3 that Raman 
spectroscopy is well suited to monitor polymorphic conversion in aqueous 
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environment due to the weak water scattering signal and simple sample preparation, 
where preparation technique for XRPD such as filtration and grinding are avoided. 
Therefore, the study presented in this chapter was conducted following the findings 
presented in Chapter 3 in order to obtain an insight into the mechanism of interaction 
between CBZ and various excipients in aqueous suspension. 
4.2 Materials and Methods 
4.2.1 Materials 
CBZ forms were supplied and prepared as specified in Section 2.1.1. The particle size 
of CBZ forms III and I was controlled by sieving to the range 180 to 250 µm (Test 
sieves, Endecotts Ltd, England). The specific surface areas of form III and I were 
estimated based on their respective SEM images. Adobe Photoshop 7.0 (San Jose, 
USA) was used to remove the background from SEM photos and the two dimensional 
specific surface area of particles was calculated by AnalySIS Pro 3 .1 (Soft Imaging 
Sytem GmbH, Germany) (100 particles were randomly selected for each form). 
Methyl cellulose (MC) with molecular weights of 14,000; 41,000; 88,000, 
hydroxypropyl methylcellulose (HPMC) with a molecular weight of 26,000, 
hydroxypropyl cellulose (HPC) with a molecular weight of 80,000, 2-hydroxyethyl 
cellulose (HEC) with a molecular weight of 720,000, sodium carboxymethyl cellulose 
(CMC) with a molecular weight of 700,000, and cellobiose were purchased from 
Sigma Chemical Co. (St. Louis, MO). Poly(vinyl pyrrolidone) (PVP) with molecular 
weights of 24,500 and 44,000, and polyethylene glycol (PEG) with a molecular 
weight of 6,000 were obtained from BDH Chemicals Ltd. (Poole England). PVP 
(Kollidon 90F) with a molecular weight of 1,000,000 - 1,500,000, PVP - vinyl acetate 
copolymer at a weight ratio of -6:4 (PVPN A) and a molecular weight of 45,000 -
70,000, and polyethylene oxide - polypropylene oxide copolymer (PEO/PPO) with a 
molecular weight of 8,400 were obtained from BASF, Germany. N-methyl-2-
pyrrolidone was purchased from ISP Technologies, Inc. (Wayne, NJ). All excipients 
were used without further purification. Molecular weights of the polymers were 
supplied by the respective companies. 
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The chemical structures of CBZ and the various excipients used in this study are 
presented in Figure 4.1. The excipients can be classified into three groups according 
to their molecular characteristics: 
Group 1: cellulose de1ivatives and cellobiose - having both hydrogen bond donor and 
acceptor groups in their ling structure 
Group 2: PVPN A, PVP and methylpyrrolidone - only having hydrogen bond 
acceptor groups 
Group 3: PEG and PEO/PPO - having hydrogen bond donor groups only at the two 















Cellulose (R = H) or Cellulose derivatives (R from the list below) 
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Cellulose derivatives -R DS* 
Methyl cellulose (MC) -CH3, 1.50-1.90 (1.70) 
Hydroxypropyl methylcellulose - CH2CH(OH)CH3 , -0.50(0.50), 
(HPMC) -CH3 -2.50 (2.50) 
Hydroxypropyl cellulose (HPC) - CH2CH(OH)CH3, -2.00 (2.00) 
Hydroxyethyl cellulose (HEC) -CH2CH20H, 1.50 (1.50) 
Sodium carboxymethyl cellulose -CH2COONa, 0.86 (0.86) 
(CMC) 
*DS (Degree of Substitution) were obtained from Sigma information sheets. 
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Figure 4.1 Structures of CBZ and excipients used in this study. 
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4.2.2 Measurements 
4.2.2.1. X-ray powder diffraction (XRPD) 
XRPD measurements were performed using the method specified in Section 2.2.1. 
4.2.2.2. FT-Raman spectroscopy 
The Raman analysis were carried out using the method describe in Section 2.2.2. 
4.2.2.3. Scanning electron microscopy (SEM) 
SEM micrographs were taken for the initial CBZ forms III and I using the method 
described in 2.2.6. 
4.2.3 Mixture quantitation 
4.2.3.1. Binary mixtures for the calibration models 
CBZ anhydrate forms III and I were blended separately with DH to form binary 
physical mixtures at 20 % (w/w) intervals from O to 100 % CBZ anhydrate in DH 
(20 mg per sample). Each concentration was prepared in triplicate and measured by 
Raman spectroscopy. 
4.2.3.2. Multivariate analyses 
Multivariate evaluation was performed on the recorded spectral data using the method 
specific in Section 2.2.7. 
4.2.3.3. Conversion of CEZ in various excipient solutions 
CBZ ( 40 mg) was dispersed independently in triplicate into each 2 ml aqueous 
excipient solution (0.1 % w/v) for 30 min at room temperature, and then recovered by 
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pouring the whole dispersion onto two layers of filtration paper to remove excess 
water. The CBZ residue was then transferred into three sample holders consecutively, 
and analyzed immediately. CBZ was also dispersed into pure distilled water under the 
same conditions and recovered using the same method. 
4.2.4 Solubility parameter calculation 
The Hansen solubility parameters of all the excipients were calculated according to 
their chemical structures using the approach of HoftyzerN an Krevelen [205]. 
4.3 Results and Discussion 
4.3.1 Characterization of the initial CBZ polymorphs and the recovered 
samples from dispersing CBZ in various excipient solutions for 30 min 
4.3.1.1. XRPD 
DH is the most stable form of CBZ in aqueous suspension, and both CBZ forms III 
and I started converting to the DH upon contact with water. The X-ray diffractograms 
of the initial CBZ forms III, I and the DH are shown in Figure 4.2 (diffractograms a, b 
and c). 
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Figure 4.2 X-ray diffractograms of different CBZ forms and of recovered samples 
(rec) from various excipient solutions (0.1 % w/v): a) CBZ form III; b) CBZ form I; c) 
CBZ DH; d) rec from form III in PVP solution; e) rec from form I in PVP solution; f) 
rec from form III in HEC solution; g) rec from form I in PEG solution; h) rec from 
form III in PEO/PPO solution; i) rec from form I in cellobiose solution. 
XRPD was also catTied out for the recovered samples of forms III and I dispersed 
separately in the excipient solutions for 30 min. The results obtained for some 
CBZ/excipient combinations are also shown in Figure 4.2 (diffractograms d to i). All 
diffractograms have two common features. Firstly, no peaks due to excipients could 
be observed. This is due to the very low concentration (0.1 % w/v) of excipient in the 
preparation, and the amorphous nature of most of the excipients used. Secondly, all 
peaks could be attributed to the DH and form III or I respectively indicating the 
absence of other polymorphic forms of CBZ. 
Since the samples were measured directly after recovery without fmther drying and 
grinding, inhomogeneous particle size distribution may induce some differences in the 
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peak pattern of XRPD due to preferred orientation which is especially common for 
needle like crystals such as CBZ form I and DH. However, there were clear 
differences in the degree of the DH formation between the recovered samples. The 
samples recovered from PVP solutions (Figure 4.2d and 4.2e) were similar to their 
initial forms (Figure 4.2a and 4.2b), indicating a complete inhibition of conversion 
after 30 min dispersion. The characteristic DH peaks at 9.0 and 12.3° (28) appeared in 
the samples recovered from form III dispersed in HEC solution and form I dispersed 
in PEG solution (Figure 4.2f and 4.2g), and became dominant for the samples 
recovered from CBZ dispersions containing PEO/PPO and cellobiose respectively 
(Figure 4.2h and 4.2i). There appeared to be a decrease in the ability of the excipients 
to protect against DH formation in the sequence PVP > HEC or PEG > PEO/PPO or 
cellobiose. 
4.3.1.2. DSC 
The thermal behavior of the initial CBZ forms III, I and pure DH is shown in Figure 
4.3 (thermograms a, b and c). Recovered samples from various excipient solutions 
were also characterized by DSC. Figure 4.3 shows the thermograms of the same 
CBZ/excipient systems as shown in Figure 4.2. There was no apparent conversion to 
the DH for the samples recovered from PVP solution since no water endotherm can be 
seen in Figure 4.3 (thermograms d and e). However, water evaporation started to 
appear in the CBZ samples with excipients that showed less ability to protect against 
hydrate formation such as HEC, PEG, PEO/PPO and cellobiose (thermograms 4.3f -
3i). 
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Figure 4.3 DSC thermographs of different CBZ forms and of recovered samples (rec) 
from various excipient solutions (0.1 % w/v): a) CBZ form III; b) CBZ form I; c) CBZ 
DH; d) rec from form III in PVP solution; e) rec from form I in PVP solution; f) rec 
from form III in HEC solution; g) rec form form I in PEG solution; h) rec from form 
III in PEO/PPO solution; i) rec from form I in cellobiose solution. 
Some differences in the thermal behavior of form III and DH in the recovered samples 
compared with their pure forms were found as shown in Figure 4.3. The water loss 
endotherm of DH in the recovered samples was about 9 °C lower than that in the pure 
DH, and the form III transition peak was broad and around 164 °C, i.e. about 11 °C 
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lower than for the pure form III. These differences are possibly due to the presence of 
the respective other form as described above in these recovered samples. Similar 
changes in the form III thermogram have been reported for mixtures of forms III and I 
[201]. 
4.3.2 Raman spectroscopy 
Raman spectra of the CBZ forms and the recovered samples of forms III and I 
dispersed separately in various excipient solutions are shown in Figures 4.4 and 4.5. 
Two excipients were randomly selected from each group, and again no peaks 
belonging to the excipients or other polymorphic forms of CBZ were found, 
confirming the results obtained from XRPD and DSC. However, the different 
conversion extent of CBZ form III or I to the DH due to the influence of the 
excipients in the solution can be clearly observed, especially in the spectral features 
indicated by the arrows in Figures 4.4 and 4.5. 
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3200 3000 1200 1000 800 600 400 200 
Wavenumber [cm-1] 
Figure 4.4 Raman spectra of different CBZ forms and of recovered samples from 
form III dispersed in various excipient solutions (0.1 % w/v) for 30 min: a) CBZ form 
III; b) rec from HPMC solution; c) rec from PVP solution; d) rec from HEC solution; 
e) rec from CMC solution; f) rec from cellobiose solution; g) rec from PEO/PPO 
solution; h) CBZ DH. (A1rnws show area of spectral differences between the 
samples). 
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Figure 4.5 Raman spectra of different CBZ forms and of recovered samples from 
form I dispersed in various excipient solutions (0.1 % w/v) for 30 min: a) CBZ form I; 
b) rec from HPMC solution; c) rec from PVP solution; d) rec from HEC solution; e) 
rec from PEO/PPO solution; f) rec from CMC solution; g) rec from cellobiose 
solution; h) CBZ DH. (Anows show area of spectral differences between the 
samples). 
4.3.3 Quantitative studies 
4.3.3.1. Quantitation of binary mixtures 
Since there was no interference from the excipients or other polymorphic forms of 
CBZ, calibration models built of binary mixtures of CBZ forms III or I respectively 
with the DH were used for quantifying the conversion of CBZ in each excipient 
solution. The generation of these calibration models has been described in detail in the 
method section in Chapter 3 [206]. 
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4.3.3.2. Conversion of CBZ dispersed in various excipient solutions 
In order to show the effects of the excipients on the conversion of CBZ, the 
conversion of CBZ forms III and I was plotted as the percentage of remaining CBZ 
versus the solubility parameter calculated for each excipient (Figure 4.6). 
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Figure 4.6 Percentage of remaining CBZ forms III (a) and I (b) after 30 mm of 
dispersion versus the solubility parameter of excipients in group 1 (1111), group 2 (•), 
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group 3 (&.), (the conversion extent of forms III and I in aqueous suspension 
containing no excipient is shown by the two dotted lines). #three different grades of 
MC and PVP were used. 
It has been reported that HPMC can completely inhibit the conversion of CBZ form 
III to the DH in aqueous suspension, because of a structural match between form III 
and HPMC as mentioned above [204]. Excipients in group 1 were selected based on 
the criterion of having a similar cellulose ring structure to HPMC, and thus should 
have the potential to completely inhibit the conversion. 
As shown in Figures 4.4 and 4.6a, the Raman results for HPMC agreed well with that 
published earlier [204]. There was no conversion to the DH after dispersing form III 
in HPMC solution for 30 min, and this was the same for two other excipients in group 
1 - MC and HPC, which have higher solubility parameters than HPMC. However, 
partial conversion to the DH occmTed when CBZ was dispersed in HEC (especially 
for form I), and there appeared to be a trend of increasing conversion with increasing 
solubility parameters of the group 1 excipients used. 
The difference in the inhibition ability of these excipients is unlikely to be caused by a 
modulation of their ability to H-bond with CBZ, since there are no structural 
differences in the cellulose ring structure present in this class of excipients. Also, 
since the polymer solutions had a very low concentration (0.1 % w/v) and CBZ is a 
neutral drug, factors such as pH and viscosity are unlikely to play an important role. 
Therefore, the difference may be mainly related to the solubility of these excipients in 
water. Polymers such as HPMC, MC, HPC or HEC which have lower solubility 
parameters and thus higher hydrophobicity than HEC, CMC or cellobiose, can 
provide stronger protection for the CBZ particles against water attack, because they 
are more likely to be adsorbed on the CBZ particle surface than in the aqueous phase. 
Simonelli et al. (1970) have previously reported the inhibition of the crystal growth of 
sulfathiazole by PVP, suggesting both binding and/or adsorption of PVP to the crystal 
surface. Also, Lechuga-Ballesteros and Rodriguez-Hornedo (1993) reported the 
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The importance of structural matching for the cellulose derivatives, however, is 
highlighted by the fact that cellobiose, which may be regarded as the monomer unit of 
cellulose despite its high solubility parameter, was still able to partially inhibit CBZ 
form III conversion. 
A similar trend can also be seen for CBZ form I dispersed in the excipients of group 1 
(Figure 4.6b). However, the conversion extent greatly increased when solubility 
parameters became higher than that of HEC, which may be caused by the higher 
specific surface area of form I (43 mm- 1) than form III (17.2 mm-1). This can also be 
seen from their morphology (Figure 4.7) where form I consists of needle like 
aggregates whereas form III consists of separate prism like crystals. The inhibition of 
conversion of form I was thus more difficult than for form III. 
Figure 4.7 SEM micrographs of CBZ polymorphs: a) form I; b) form III (horizontal 
scale bars: 1.00 mm). 
For the excipients in group 2, complete inhibition of forms III and I conversion was 
observed for PVP and PVPN A, which have similar solubility parameters to HPMC, 
but Jack the strong structure matching to CBZ. PVP and PVPN A however, are strong 
hydrogen bond acceptors due to the oxygen of their carbonyl group, which can bind to 
one of the hydrogens attached to the nitrogen of CBZ. This hydrogen bonding is 
likely to be formed as one hydrogen atom of CBZ is not involved in the CBZ dimer 
formation. Therefore, a high structure match as for HPMC may not be necessary 
when the excipients have appropriate hydrophobicity (solubility parameters lower 
than 27.0 MPa112) and can form relatively strong hydrogen bonds with CBZ. 
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Methylpyrrolidone, which might be regarded as a "PVP monomer", was also used in 
this study. It showed much less inhibition ability even though it has a similar 
solubility parameter to PVP. We explain this as being a consequence of size 
difference between the "monomer" and polymer. It is plausible that PVP can undergo 
several interactions with the surface of the CBZ crystals. Methylpyrrolidone, as a 
single molecule can not do this, thus it only partially inhibited the conversion and 
showed an especially low inhibition ability for the bigger surface area samples of 
form I. 
It must be mentioned that differences in the diffusion rate may also be a factor 
inducing the differences in inhibition ability between PVP and methylpyrrolidone. 
However, under the current conditions, while the influence of polymer size on the 
conversion could be observed when the size difference was significant such as 
between polymer and monomer, polymers with different molecular weights showed 
the same inhibition ability. As shown in Figure 4.6, there was no difference in the 
conversion extent of CBZ among the three grades of PVP, or among the three grades 
ofMC. 
The excipients in group 3 - PEG and PEO/PPO both showed weak inhibition ability 
although they have low solubility parameters. This may be explained by their weak 
hydrogen bonding with CBZ. As shown in Figure 4.1, both PEG and PEO/PPO have 
hydrogen bond donor groups only on the two ends of their polymer chain. Moreover, 
the oxygen atom of CBZ is already involved in the CBZ dimer formation. Although 
there are also oxygen atoms in PEG and PEO/PPO, which are hydrogen bond 
acceptors [207, 208], the hydrogen bonding interaction with CBZ to the ether oxygen 
is likely to be weaker than to the carbonyl oxygen of PVP or PVP/V A. 
From the cunent study, it can be concluded that there are two important prerequisites 
for the inhibition of polymorphic transition of CBZ forms III and I to the DH by 
excipients in dilute (0.1 % w/v) aqueous solution. Firstly, the possibility of hydrogen 
bonding between the drug and excipients, where hydrogen bond acceptor groups (as 
in PVP) appeared to be of some importance for the inhibition. Secondly, the 
excipients must have sufficient hydrophobicity (expressed in this study by the 
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solubility parameter) to increase the likelihood of interactions with the CBZ crystal 
surface. 
4.4 Chapter summary 
The influence of various excipients on the conversion of CBZ to the DH in aqueous 
solution was investigated in this study, in an attempt to clarify the mechanisms 
underpinning the effect of polymeric excipients on the polymorphic conversion in 
aqueous dispersion. Katzhendler et al. (1998) emphasised hydrogen bond formation 
through a significant structural matching between the excipient and drug as important, 
while Simonelli et al. (1970) suggested surface adsorption as the only necessity for 
complete inhibition of PVP to the growth of sulfathiazole crystals. For the selection of 
excipients in this study, we have found that both hydrogen bonding ability and a 
sufficient hydrophobicity are important to the inhibition ability of excipients although 
it is difficult to compare the relative importance of the two factors. Furthermore, in 
this study Raman spectroscopy has been successfully used to investigate the 
polymorphic conversion of a drug in suspensions containing various excipients, 
offering the potential of fast and reliable excipient screening. 
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Chapter 5 
Visualizing the hydrate formation of single carbamazepine crystals in 
aqueous suspension using imaging techniques* 
* The work presented in this chapter has been previously published as a paper in the European Journal 
of Pharmaceutics and Biopharmaceutics 64 (2006): 326- 335. 
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5.1 Introduction 
Visual characterisation of any solid material is extremely important in drug 
development. Different microscopic techniques are widely used especially in early 
stage evaluation of drug candidates when only a limited amount of material is 
available. Microscopy can be utilised in the evaluation of particle morphology e.g. to 
build estimations of the particle size distribution, to determine relative crystallinity 
and often to acquire crystallographic information as well[3]. 
In order to get qualitative or quantitative information about patiicle morphology it is 
often necessary to obtain some appreciation of its three-dimensional (3-D) nature. A 
certain amount of 3-D characteristics is often required in order to get qualitative or 
quantitative information about particle morphology. Depending on how the images 
are produced different amounts of 3-D features can be distinguished; for instance, 
optical microscopy has a poorer depth of field and lower resolution than scanning 
electron microscopy (SEM). However, both optical microscopy and SEM are 
frequently used in the characterisation of pharmaceutical solids and they are often 
complementary in problem solving. The use of SEM in various applications probing 
morphology has been reviewed by Newman and Brittain [1]. However, in recent 
research on drug crystals, polymorphism and polymorphic transitions, SEM images 
have provided qualitative evidence and the quantification has been provided by other 
techniques [196, 198, 209, 210]. Consequently the interpretation of occuning 
phenomena based on measurements with solid-state characterisation techniques, 
including spectroscopic methods, are often not fully complemented by the use of 
imaging techniques. 
The possible applications of optical microscopy and SEM m crystal studies are 
numerous including defect characterisation, monitoring of face dependent 
phenomena, visualisation of dissolution mechanisms and interactions between drug 
crystals and excipients. In this study, the visualization power of SEM is demonstrated 
in an anhydrate to hydrate conversion study using carbamazepine (CBZ). Light 
microscopy has been explored for this purpose by Laine et al. as early as 1984, where 
the whole hydrate formation process of CBZ in aqueous suspension and the related 
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mechanism were described based on the images of the CBZ crystals [184]. More 
recently (2006), as presented in the Chapter 3, quantitative studies of the conversion 
of three different CBZ polymorphic forms I, II and III, and also mixtures of forms I 
and III, to the DH in aqueous suspension was investigated by our group using Raman 
spectroscopy [206]. Possible conversion mechanisms of the different polymorphic 
forms to the DH were suggested based on differences in crystal morphology. 
Interestingly, for all polymorphic forms (particle size 180 - 250 µm) used in that 
study, an incomplete conversion after 210 min of dispersion in water was found. This 
was assumed to be caused by the deactivation of the original surface by a coating of 
DH crystals, which was also suggested by other authors[152, 184]. Such coverage 
would impede further penetration of water molecules into the core of the unconverted 
CBZ. The influence of excipients on the conversion kinetics of CBZ polymorphs to 
the DH was also investigated by our group as reported in Chapter 4 [102]. 
As described in Chapter 4, excipients having both low solubility parameters ( < 27 .0 
MPa112) and strong hydrogen bonding groups could inhibit the conversion completely. 
Such excipients include hydroxypropyl cellulose (HPC) and poly(vinyl pyrrolidone) 
(PVP). The inhibition ability decreased with increasing solubility parameter, e.g. for 
sodium carboxymethylcellulose (CMC). Excipients such as polyethylene glycol 
(PEG) lacking strong hydrogen bonding groups, were of poor inhibition ability 
although they have a low solubility parameter ( < 21.0 MPa112). However, even with a 
better understanding of the conversion kinetics of bulk CBZ power and the influence 
of excipients on the kinetics based on the quantitative studies described above, 
questions regarding the hydrate formation process of single crystals remain open: Is 
surface coverage of DH crystals on the initial CBZ crystals the reason for the 
observed incomplete conversion of CBZ in water? Is the hydrogen bonding with 
water in CBZ face-dependent? Do different faces of CBZ interact differently with the 
different excipients? Recently, SEM was used in the investigation of DH growth on 
the surface of single CBZ crystals [152] but the focus of data analysis was not on 
image information from SEM. The efforts of applying imaging techniques on more 
fundamental investigations have always been limited compared with the use of other 
techniques such as X-ray powder diffraction, and more recently IR and Raman 
spectroscopy, which have all been tried in various ways to extract more information 
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from CBZ suspensions [87, 151, 154, 180, 181, 189, 196, 200, 202, 203, 206, 209, 
211, 212]. 
Therefore, the aim of the study reported in the present chapter is to apply SEM as a 
visualisation technique to explore the relation between the crystal morphology and the 
anhydrate-hydrate conversion process. Also, as the growth of the DH crystals is 
related to molecular interactions between CBZ and water molecules, conversion 
differences between the important crystal faces are studied and discussed in terms of 
the molecular arrangements along the crystal faces. Furthermore, the effect of 
excipients on the conversion of CBZ crystals is investigated. 
5.2 Materials and Methods 
5.2.1 Materials 
CBZ form III was supplied as specified in Section 2.2.1. Methanol (HPLC grade) was 
obtained from Merck Ltd. (Palmerston, New Zealand). HPC with a nominal molecular 
weight of 80,000 and sodium carboxymethyl cellulose (CMC) with a nominal 
molecular weight of 90,000 were purchased from Sigma Chemical Co. (St. Louis, 
MO). PVP with a nominal molecular weight of 24,500 and PEG with a nominal 
molecular weight of 6,000 were obtained from BDH Chemicals Ltd. (Poole, England). 
5.2.2 Methods 
5.2.2.1. Growth of single CBZ crystals: 
Single crystals were grown by cooling a saturated solution of CBZ form III (p-
monoclinic form) (1 g) dissolved in methanol (15 ml), and allowing methanol to 
evaporate slowly. 
5.2.2.2. Crystal morphology of single CBZ crystals: 
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SEM micrographs were taken of the initial CBZ single crystal, and also of the crystals 
recovered after immersion in distilled water or various excipient solutions at room 
temperature without stirring. In total, approximately 100 crystals per sample were 
examined with SEM and typical sample crystals are presented. The detailed method of 
SEM was specified in Section 2.2.6. 
The interplanar angles between the faces of a typical CBZ crystal were measured 
using a two-circle reflecting goniometer, and the Miller indices of the faces were 
calculated based on the equation which relates the interplanar angles of p-monoclinic 
crystal system to the unit cell parameters reported for CBZ [145]. 
5.2.2.3. FT-Raman spectroscopic techniques 
Raman and Raman microscopy measurements were conducted using the method 
specified in Section 2.2.2 and 2.2.3 respectively. 
5.3 Results and Discussion 
5.3.1 Characterization of the initial single CBZ crystal 
The morphology of a typical CBZ crystal and the Miller indices of three faces [(100), 
(001) and (010)] are shown in Figure 5.1. 
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5.3.2 Hydrate formation of CBZ crystals 
5.3.2.1. SEM 
Figure 5.2(a - c) shows the SEM images of three selected single crystals (left) and 
details of their respective surfaces at a higher magnification (right). The magnified 
area is indicated by a rectangle in the micrographs on the left side. All the crystals in 
Figure 5.2 were immersed in water for less than one hour. 
Figure 5.2 SEM micrographs of CBZ crystals immersed in water for less than one 
hour. The whole crystals are shown on the left (a - c), and the areas indicated by 
rectangles are shown respectively on the right at a higher magnification. Arrows are 
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As described by Laine and co-workers, the morphology of DH crystals resembled, 
clusters of whiskers [184]. The obvious morphological differences between CBZ 
anhydrate (form III) and the DH greatly facilitate the detection of the starting point of 
the hydrate formation as well as the whole hydrate formation process (see below). As 
indicated by the arrows in Figure 5.2, DH needles could be observed at surface defect 
structures of each crystal after less than 1 hour immersion in water. However, for the 
areas without obvious defects, no needles could be seen indicating no conversion. 
Therefore, the SEM images indicate that the initiation of the hydrate formation 
process is due to the presence of defect structures and that these are a more important 
driving force to initiate hydrate formation than the nature of crystal faces. This is 
plausible as it is widely accepted that the crystal growth behaviour has an extreme 
dependence on defect strnctures in the crystallization process [213]. 
It was noted that the surface morphology of the whole crystal also changed after 1 
hour immersion in water compared with their original surface morphology (the 
magnified surface of the initial crystal is shown in Figure 5.3a (right)). The surfaces 
eroded and surface roughness increased, which is a clear indication of CBZ dissolving 
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Figure 5.3 SEM micrographs of CBZ crystals during the hydrate formation process: 
a) initial CBZ crystal; b) immersed in water for 3 hours; c) immersed in water for 6 
hours; d) immersed in water for 12 hours; e) immersed in water for 18 hours. The 
whole crystals are shown on the left ( a - e ), and the areas indicated by rectangles are 
shown on the right at a higher magnification. 
For crystals without any obvious surface defects as shown in Figure 5.3a (left), it is 
hard to predict the starting sites for hydrate formation. However, as the conversion 
process proceeded (from O to 18 hours), the surface erosion due to CBZ dissolution 
increased as shown in the magnified micrographs 5.3(b - e) (right). Also, differences 
in the degree of hydrate formation between faces became clear. As shown in Figures 
5.3c (left), all faces except (100) and (001) were heavily covered with DH needles 
after 6 hours immersion, whereas in Figure 5.3d (left), after another 6 hours 
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immersion, needles have also started growing on (100) and (001) faces, but some 
parts of (100) face were still without DH. After 18 hours immersion, only a very small 
space of unconverted CBZ could still be observed on the (100) face (Figure 5.3e 
(left)). Therefore, the (100) face showed the slowest conversion to DH needles. It has 
been shown that in crystal growth the largest faces form when the crystal phase 
molecules do not strongly interact with solvent; strongly interacting faces tend to be 
smaller in size [ 17, 214]. Therefore, for the single crystals (grown from methanol), the 
largest face, ( 100), should be the one interacting least with the solvent molecules 
(methanol). Since methanol and water are both polar, protic solvents [215], the face 
interacting least with methanol should also be the most inactive one in water. This 
prediction agrees with the electron microscopical observations in this study (Figure 
5.3). It is possible that the formation of DH nuclei on the (100) face is greatly 
hampered by its slow dissolution (since it is the weakest face to interact with water). It 
is also likely that the dissolved CBZ from this face is supplied to the sites where DH 
nuclei have already formed to promote whiskers growth there. This also explains why 
the DH needles arrange in a fan-like shape as they mainly grew from a few DH nuclei 
which worked as the centre points for the growth and then spread to the surrounding 
areas. Interestingly, Laine et al. (1984) also described such orientated growing 
structure of DH (clusters of whiskers) and mentioned that this orientation could be an 
important factor for the DH growth [184]. 
It can also be seen in Figure 5.3e (left) that all the faces of the initial CBZ were finally 
covered with DH needles. This further confirmed the assumption raised in our 
previous study that the incomplete conversion of CBZ polymorphs was due to the 
surface coverage of the DH formed slowing down the conversion process [206]. 
Rodrfguez-Hornedo and Murphy (2004) have not reported any visual evidence for 
face differences during the hydrate formation of single CBZ crystals. However, our 
results showed a clear difference between the (100) face and the other faces. 
The chemical structure of CBZ and its dimer (present in the crystalline form of CBZ) 
are shown in Figure 5.4a and 5.4b respectively (the possible hydrogen binding sites of 
CBZ are indicated by the asterisks*). 
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CBZ CBZdimer 
Figure 5.4 Chemical structures of CBZ and its dimer. 
It is well known that the formation of the DH is due to the interaction of the hydrogen 
bonding groups of CBZ and water molecules [25, 216]. The slower hydrate formation 
rate of the (100) face on the CBZ crystal compared with the other faces also indicated 
its poorer hydrogen bonding abilities. These are primarily due to the CO and NH2 
groups, which are fewer in number and/or less exposed at the (100) face. 
To better understand the molecular arrangement along the faces of the CBZ single 
crystal, Figures 5.5a and b show the [(100) and (010)] faces, and [(100) and (001)] 
faces respectively (illustrated with the crystal structure visualization software, 
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Figure 5.5 Molecular structure of the two faces [(100) and (010)] (a) , and of the two 
faces [(100) and (001)] (b) . 
These figures can be used to explore the difference in hydrogen bonding groups 
between these three faces of the CBZ crystal. In Figure 5.5a, the (010) face (green) is 
characterized by polar NH groups and non-polar CH groups from the ring structures, 
whereas the (100) face (red), is mainly characterised by non-polar hydrocarbon (CH) 
groups from the ring structures of the CBZ molecule. Although polar carbonyl groups 
are present, these are not as frequently occurring as the polar NH groups on the (010) 
face. Also, for the (001) face (blue) in Figure 5.5b, both polar NH and carbonyl 
groups are frequently occurring, indicating the stronger hydrogen bonding ability of 
the (001) face compared to the (100) face (red). 
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5.3.2.2. FT-Raman spectra 
The initial CBZ crystal (with no contact to water) shown in Figure 5.3a and the 
incompletely hydrated crystal shown in Figure 5.3d were also used for Raman 
measurements in order to further confirm the chemical structure of the initial CBZ and 
the needles grown on its surface. Although FT-Raman has been used in on-line 
measurements of the conversion of CBZ to the DH in a microliter fluid cell [119], the 
growth of needles on the surface of the single CBZ crystals using FT-Raman 
microscopy presented in this work has not been reported previously. 
Figure 5.6 shows micrographs of the surface of the crystals shown in Figures 5.3a and 
5.3d taken with a Raman microscope. The areas measured by the Raman laser on the 
crystal are indicated by the ellipses in Figure 5.6, and the labels inside the ellipses (b, 
c, d) correspond to the spectra shown in Figure 5.7. 
Figure 5.6 Micrographs of the surface of CBZ crystals taken by Raman microscopy 
(40 x magnification): ellipse (b) is on the surface of initial CBZ; ellipses (c) and (d) 
are on the surface of the CBZ recovered from 12 hours immersion in water: (c) is the 















Chapter 5 Visualizing the hydrate formation of carbamazepine 
1600 1400 1200 1000 
-1 
Wavenumber [cm ] 
800 600 400 
Figure 5.7 FT-Raman spectra of: a) CBZ form III powder; b) area on the smooth 
surface of the initial crystal without contacting water; c) area without needles on the 
incompletely converted crystal; d) area covered with needles on the incompletely 
conve1ted crystal; e) CBZ DH powder. Peaks showing obvious differences between 
CBZ and the DH are indicated by the arrows. 
The orientation of a crystalline sample can result in intensity changes in Raman 
spectra [217]. In our studies there are some small intensity differences between the 
powder sample (which is randomly oriented, Figure 5.7a) and the crystalline samples 
(Figure 5.7b and c). A small shoulder at 1588 cm- 1 due to the stretching of C=C bonds 
becomes slightly more obvious in the crystalline samples compared to the powder 
sample. Nevertheless, it is clear that the spectra from the smooth surface at (100) face 
of the initial CBZ (Figure 5.7b) and that of the surface at (100) face without any 
needles (Figure 5.7c) are that of the CBZ form III. Also, the Raman spectrum from 
the surface covered with needles is similar to that of DH powder (Figure 5.7e). 
Although differences between form III and DH can be observed in the whole spectral 
range shown in Figure 5.7 (as indicated by the arrows) , the most distinguishing 
difference is the band pattern at around 1042 cm- 1 (aromatic C-H bend). The distinct 
band pattern of DH at 1040 and 1027 cm- 1 are reproduced in the spectrum of the 
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converted CBZ single crystal are DH, and the area without needles coverage is the 
unconverted CBZ. 
5.3.2.3. Hydrate formation of CBZ crystals in the presence of excipients 
Morphological differences of CBZ crystals immersed in water and various excipient 
solutions are shown in Figure 5 .8. 
a) CBZ immersed in water for - 2 hours 
b) CBZ immersed in HPC (1 % w/v) for - 18 hours 
c) CBZ immersed in PVP (1 % w/v) for - 18 hours 
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d) CBZ immersed in PEG (1 % w/v) for - 18 hours 
' .. e) CBZ immersed in CMC (1 % w/v, pH= 7.5) for - 18 hours 
f) CBZ immersed in CMC (1 % w/v, pH= 3.0) for - 18 hours 
g) CBZ immersed in water for - 18 hours 
I~ 
109 
Chapter 5 Visualizing the hydrate formation of carbamazepine 
Figure 5.8 SEM micrographs of CBZ crystals immersed in water for 2 hours (a) and 
for 18 hours (g) and in various excipient solutions (b - f) for 18 hours. The whole 
crystals are shown on the left (a - g), and the areas indicated by rectangles are shown 
on the right (a - g) at a higher magnification. 
Again, the slow dissolution of the CBZ crystals can be clearly seen by SEM as the 
surface became rough with rigid edges as a function of time. However, these rigid 
edges did not consist of DH, with its typical fan-like shaped needles. This was also 
confirmed by FT-Raman microscopy. 
The effect of various excipients on the conversion of the CBZ to the DH can also be 
observed directly from the SEM micrographs in Figure 5.8. All the excipients - HPC, 
PVP, CMC and PEG retarded the conversion to some extent. Both HPC and PVP 
showed the highest inhibition ability. They completely inhibited the conversion for 18 
hours (Figure 5.8B and C (left)). Taylor and co-workers have demonstrated that the 
particle size of CBZ crystals dispersed in a PVP solution decreased indicating the 
dissolution of the crystals [218]. It has been shown clearly in this study that crystals 
immersed in the excipients with an inhibitory effect keep dissolving, resulting in a 
rough surface without any formation of the DH nuclei. 
CMC (pH= 7.5) and PEG also inhibited the hydrate formation to some extent (Figure 
5.8D and E (left)), and the (100) face was the slowest face for the DH growth in these 
solutions. Since CMC is an anionic polymer, medium with a low pH value (3.0) was 
also used to investigate the pH influence on the hydrate formation. Interestingly, no 
DH needles could be observed after 18 hours immersion (Figure 5.8F (left)). Again, 
the surface roughness of the CBZ crystals increased greatly (Figure 5.8F (right)), 
implying dissolution of CBZ in the CMC solution at pH = 3.0 without conversion. 
This strongly retarded conversion at decreased pH agreed well with the suggestions 
raised from our previous study. The polarity (degree of ionization) of CMC (pKa, cmc 
= 4.3) in water decreases with the decreasing pH (from 7.5 to 3.0), which results in its 
enhanced surface adsorption to the CBZ crystals in the dispersion. In general, the 
SEM findings confirmed our previous quantitative studies [102]. Whilst it is difficult 
to compare the relative degree of inhibition ability between HPC and PVP, or between 
CMC (at pH 7.5) and PEG from the SEM micrographs above since the size and shape 
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of the initial crystals immersed in the excpient solutions are not all exactly the same, 
the structural information is unique to the microscopic investigation, and clarified the 
quantitative behavior detected by Raman spectroscopy [102]. 
5.4 Chapter summary 
In this study, the power and potential of SEM in the investigation of pharmaceutical 
polymorphic conversions has been demonstrated. The hydrate formation phenomena 
of CBZ were clearly observed with SEM imaging and a plausible explanation for the 
partial conversion of CBZ to the DH was formed based on the growth characteristics 
of the DH needles. Also, a better understanding of factors such as defects, face 
differences, influence of excipients, which are all of importance to the physical 
stability of CBZ, was gained from SEM images; such insights are not expected to be 
directly detectable using bulk techniques. 
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Influence of hydrate formation on the dissolution of 
carbamazepine compacts* 
* The work presented in this chapter has been accepted for publication in the Journal of Pharmaceutical 
Sciences 2006. 
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6.1 Introduction 
In vitro dissolution tests have been accepted as indispensable quality-control 
procedures for drugs with low aqueous solubility and whose absorption is dissolution 
rate limited (class II drugs with respect to Biopharmaceutics Classification System, 
BCS), since they may provide important information about the in vivo absorption of 
pharmaceuticals [192]. As specified in Section 4.1, CBZ belongs to Class 2 of BCS. 
Therefore in vitro dissolution testing of CBZ tablets is imp01tant to ensure a good 
bioavailability [219]. 
In the past twenty years, investigations of CBZ have focused on the in vitro 
dissolution behavior and in vivo bioavailability of the drug where dissolution tests 
were employed in most studies [179, 220-226]. It was found that different CBZ forms 
have different physico-chemical prope1ties [150, 227-229] and dissolution profiles 
with CBZ dihydrate (DH) showing the slowest dissolution rate and solubility 
(approximately two thirds of that of CBZ form III) [180]. Also, dissolution testing of 
different sources of marketed CBZ tablets stored at varying temperature and humidity 
conditions has been canied out. In these studies, DH formation was reported to be the 
main cause for the changes in dissolution characteristics and clinical failure of CBZ 
tablets [155-157, 230, 231]. However, efforts usually failed when trying to find clear 
relationships between in vitro dissolution and in vivo absorption, mainly due to the 
lack of a clear understanding of the behaviour of CBZ during dissolution [157, 180, 
221, 227]. 
More recently, with the rapid development of solid state analytical techniques, the 
physical stability of different CBZ forms and the influence of pharmaceutical 
excipients on the existing form of CBZ in the formulation were investigated using 
various characterization methods (Raman/IR spectroscopy [143, 144, 196, 206, 232-
234], NMR spectroscopy [88, 203]; and scanning electron microscopy (SEM) [152, 
235]) in an attempt to thoroughly understand the in vitro dissolution behavior of CBZ 
formulations [195, 197-202]. However, these studies did not address the possibility of 
solid state changes of the initial CBZ anhydrate form during the dissolution process. 
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There are also several rep01ts concerning dissolution testing of CBZ formulations 
[193, 194, 236-240]. In these studies mostly the influence of formulation factors such 
as excipient type and content on the CBZ dissolution profiles was investigated. 
However, little information is available about how a possible solid state conversion or 
crystal habit (morphology) change may affect the dissolution profile of CBZ. It is 
therefore important to gain a better understanding of solid state transformation 
phenomena of CBZ during dissolution. For this reason the following objectives were 
set for the study reported in this chapter: firstly, to investigate the influence of the 
existing CBZ form and any solid state conversions on the dissolution behavior of 
compressed CBZ; secondly, to study the influence of excipients dissolved in the 
aqueous phase on the polymorphic changes of CBZ (and thus its dissolution) using 
different types of excipients with potential to interact with CBZ; thirdly, to observe 
the morphological changes of compressed CBZ during dissolution using SEM as a 
direct visualization method. 
6.2 Materials and Methods 
6.2.1 Materials 
CBZ form III and DH were supplied and prepared as specified in Section 2.1.1. 
CBZ form III and DH (400 mg) were weighed separately and compressed into flat-
faced compacts (12 mm in diameter and 4 mm thickness) using a hydraulic press 
(model 3392, Freds. Carver Inc., USA) at a pressure of 90 MPa and held at this 
pressure for 1 min. XPRD was used to confirm that the CBZ forms were unchanged 
after compression. 
Excipients selected for the dissolution studies were hydroxypropyl methylcellulose 
(HPMC) with a nominal molecular weight of 26,000 Da, purchased from Sigma 
Chemical Co. (St. Louis, MO) and polyethylene glycol (PEG) with a nominal 
molecular weight of 6,000 Da, obtained from BDH Chemicals Ltd. (Poole, England). 
HPMC and PEG were chosen based on our former finding presented in Chapter 5 that 
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these excipients have different inhibition ability in the conversion of CBZ to the DH 
in aqueous suspension [233]. 
6.2.2 Methods 
6.2.2.1. Dissolution procedure 
All dissolution tests were pe1formed using USP apparatus 2 (paddle method) at 50 
rpm and 37°C. A six-station dissolution apparatus (DSOO dissolution tester, Logan 
Instrument Corp.) with 200 ml dissolution media (distilled water and each excipient 
solution (0.1 % )) was used. The compacts were placed (but not attached) at the 
bottom of the dissolution vessels. The dissolution of CBZ and DH compacts was 
investigated at the initial dissolution stage (150 and 250 min respectively), where sink 
conditions were ensured [241]. However, detailed hydrodynamic conditions near the 
compact surface were not determined, and were not taken into account. Aliquots (5 
ml) were withdrawn (with replacement) at predetermined time points up to 5 h using a 
10 µm filter. The absorbances of the CBZ solutions were measured by UV 
spectrophotometry (UV-1601PC, Shimadzu), and the CBZ concentration was 
calculated based on a standard curve. CBZ USP reference standards were used for 
obtaining the standard curve [241]. Dissolution tests were carried out in triplicate and 
showed a high repeatability (coefficient of variation (CV) was less than 6 % for each 
triplicate dissolution). The mean values of the triplicate from each medium were used 
for plotting the data, and the e1rnr bars are not shown for clarity. 
6.2.2.2. Scanning electron microscopy (SEM) 
The dissolution procedures were repeated to allow SEM micrographs of compact 
samples recovered at 20 min intervals. For consistency the top surface of the 
compacts facing the paddle was chosen for SEM investigation. The surfaces of 
compacts recovered at three time points are presented in this study, representing 
morphological changes observed during the entire dissolution process. The excess 
water on the samples was gently adsorbed using a tissue and samples were then 
immediately mounted onto a strip of double-sided carbon tape and sputter coated with 
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a thin layer of gold-palladium under argon vacuum prior to SEM analysis. SEM 
micrographs were also taken using the method specified in Section 2.2.6. 
6.2.2.3. X-ray powder diffraction (XRPD) 
The diffractograms of intact, dry CBZ and DH compacts were determined by XRPD. 
Additionally, compacts placed in the dissolution apparatus were removed at 
predetermined time points. The excess liquid was removed from the compacts as 
described above and compacts were then immediately subjected to XRPD analysis. 
XRPD analysis was pe1formed using the method specified in Section 2.2.1. 
6.2.2.4. Contact angle measurement 
The contact angles between DH compacts and dissolution media were determined by 
placing one drop of each medium onto the surface of an intact DH compact, and 
photos were taken immediately after the medium was placed on the compact using a 
digital camera (Coolpix 990, Nikon, Japan). The angles between the baseline of the 
drop and the tangent at the drop boundary was analysed using the software 
TurboCAD Deluxe 10.0 (IMSI Inc., USA), using the method described by Buckton 
(1995) [242). Contact angles were determined three times for each dissolution 
medium. 
6.2.2.5. Statistical tests 
The differences in the dissolution profiles of CBZ and DH compacts in each 
dissolution medium were tested by one-way analysis of variance (ANOV A) and 
Tukey' s pairwise comparisons (significance level was 0.05) using Mini tab 12.1 
software (Minitab Ltd, USA). The contact angles between DH compacts and each 
dissolution medium were tested using the same statistical method. Linear regression 
was tested for the initial stage of each dissolution profile (0 - 10 min), and also for the 
significance of the intercept. The contact angles between DH compacts and each 
dissolution medium were tested using the same statistical method. 
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6.3 Results and Discussion 
6.3.1 Dissolution 
6.3.1.1. Compacts prepared from CBZform Jll 
The dissolution profiles of CBZ form III compacts in various dissolution media are 
shown in Figure 6.1. 
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Figure 6.1 Dissolution profiles of CBZ form III compacts in three different 
dissolution media: water (111); PEG solution (A); HPMC solution (•). The dashed 
lines (SEM A-C) indicate the time points for SEM images shown in Figure 6.2. 
The concentration of dissolved CBZ in water at 150 min (60 mg L-1) was the highest 
among all the media used, and was less than one third of the saturation solubility (Cs) 
of CBZ in water (Cs = 380 mg L-1 [152]), providing sink conditions for dissolution 
according to USP method <1088> [241]. The saturation solubility of CBZ in excipient 
solutions containing HPMC and PEG was not significantly affected by the excipients 
since the concentration of these excipients used was only 0.1 % (w/v). This is not 
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surprising since even 0.1 % sodium dodecyl sulphate solutions did not significantly 
affect the solubility of the drug [152]. 
The dissolution profiles were well fitted by a linear function at times between 10 and 
150 min. The c01Telation coefficients (R2) for all the fitted lines were~ 0.992, and all 
the profiles were significantly different at every time point (P < 0.01). However, the 
intercepts of the linear fitted lines were significantly different from zero and also 
significantly different from each other (P < 0.01). The initial stage (0 - 10 min) thus 
appeared to have a more rapid dissolution rate than the later stages for all the profiles. 
The initial dissolution process was not fitted since no data was collected during this 
period. 
From the linear p01tion of the profile, it can be concluded that the dissolution rate of 
CBZ in water (0.338 mg L-1 min-1) was the highest of all the dissolution media used, 
and also showed the highest dissolution in the initial 10 min. As the DH is the 
thermodynamically stable form of CBZ in aqueous suspension, not surprisingly the 
growth of DH needles was observed on the CBZ compacts in contact with water. This 
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(A) 20 min (B) 100 min (C) 150 min 
Figure 6.2 SEM micrographs of initial CBZ compacts and the compacts recovered 
after dissolution in each medium for 20 (A), 100 (B) and 150 min (C): water (•); 
PEG solution (A); and HPMC solution (•). (All photos were taken using the same 
magnification, bars: 500 µm) . 
The SEM images showed an increasing amount of DH over time (Figure 6.2•A - C), 
which implies that the dissolved CBZ does not quantitatively stay in solution because 
(at least partially) it is supplied to continue the DH growth. However, at the same 
time, the CBZ concentration in solution continues to increase due to the dissolution of 
the two forms (initial CBZ and the formed DH). Since the formed DH crystallised in 
needle-like crystals, the surface area available for the dissolution was greatly enlarged 
compared with the original compact surface. This increased surface area 
counterbalances the loss of dissolved CBZ from the solution which was needed for 
the growth of DH needles. Therefore, an improved dissolution of the CBZ compacts 
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in water was observed with an increased DH formation. Formation of DH is also 
exemplified in the XRPD measurements at time point 100 min in which characteristic 
DH peaks at 8.9 and 12.5° (28) (indicated by the dashed lines in Figure 6.3) can be 
observed in the recovered compacts. 
The dissolution rate of the CBZ compacts in PEG solution was slightly slower (0.314 
mg L-1 min-1) than that in water in the first 150 min (Figure 6.1). The morphology 
studies of the CBZ compacts in PEG solution showed a clear difference in the DH 
growing behaviour from those in water. There was almost no DH formation after 20 
min dissolution (Figure 6.2.AA) and even after 150 min only several fan-like shaped 
clusters of DH were found which did not cover the surface completely (Figure 
6.2.A C). Although the concentration of PEG used was very low (0.1 % w/v), these 
DH clusters were morphologically different from those loosely separated needles 
grown on the compact smface in water. This different morphology and the lower 
amount of DH needles, both contributed to a lesser increase in the surface area of the 
compact in PEG solution than that in water, and thus lead to a slower CBZ dissolution 
rate in the PEG solution than in water. 
As described above, the formation of DH was different in water and in the PEG 
solution. From our previous findings it is known that PEG can partially inhibit or at 
least slow down the polymorphic conversion of CBZ to the DH in aqueous suspension 
due to its hydrogen bonding with CBZ [233]. It can be concluded for the PEG 
solution that the slower dissolution rate may be: 1. a result of differences in the DH 
growing behaviour (morphology and amount) in water and PEG solution, and/or 2. 
caused by surface absorption of PEG onto the CBZ compacts since some interactions, 
such as hydrogen bonding, between CBZ and PEG are likely to occur in the system. 
We and others have previously shown that HPMC can completely inhibit the 
conversion of CBZ to the DH in aqueous suspension due to its strong hydrogen 
bonding ability with CBZ [87, 204, 233]. The same phenomenon was observed in the 
current study. There was no DH formation during the whole dissolution process in 
HPMC solution as shown by SEM (Figure 6.29), and confirmed by XRPD (Figure 
6.3). 
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DH 




Figure 6.3 XRPD diffractograms for the intact CBZ compacts and CBZ compacts 
recovered (rec.) from the three dissolution media after 100 min dissolution. (Dashed 
lines indicate characteristic peaks of DH). 
The dissolution rate of CBZ in water is likely to have been enhanced by the increased 
surface area from the growth of DH needles, as shown in the previous examples. This 
however, could not happen in the HPMC solution since there was no DH formation. 
Also, the strong hydrogen bonding between CBZ and HPMC may have induced a 
high surface absorption of the HPMC onto the CBZ particles, thus impeding the water 
contact with CBZ. Both or either of these factors would result in a slower dissolution 
rate (0.257 mg L-1 min-1) in HPMC solution than in both water and PEG solutions. 
It can be summarized that for the dissolution of CBZ compacts in aqueous solution, 
the conversion of CBZ to the DH could in fact enhance the dissolution rate of CBZ, 
due to the needle-like morphology of the formed DH, which leads to a substantial 
surface area increase for the dissolution. For the dissolution of CBZ compacts in PEG 
and HPMC solutions, where the excipients can inhibit the DH growth, the dissolution 
rate of CBZ compacts decreased in the same rank order as for inhibiting DH 
formation. Furthermore, the excipients are able to interact with CBZ and thus could 
potentially decrease the dissolution of the unconverted CBZ in the compacts, as the 
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access of water to the surface of CBZ particles could be impeded by the CBZ-
excipient interaction. 
6.3.1.2. Compacts prepared from CBZ dihydrate (DH) 
The dissolution profiles for the DH compacts in the first 150 min are shown in Figure 
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Figure 6.4 Dissolution profiles of DH compacts in three dissolution media: water (1111); 
PEG solution (A); HPMC solution (•). The dashed lines (SEM A-C) indicate the 
time points for SEM images shown in Figure 6.4B. 
As discussed above, the solubility of drug in excipient solutions was not likely to be 
influenced at such a low concentration of excipients used (0.1 % w/v). The DH 
compacts also dissolved in the sink conditions until 240 min since the concentration 
123 
Chapter 6 Influence of hydrate formation on the dissolution of carbamazepine 
of dissolved CBZ in all the dissolution media within 240 min was less than one third 
of Cs of DH in water (Cs= 125 mg L-1 [152]). 
The dissolution profiles in Figure 6.4A were well fitted by a linear function from 10 -
150 min. The correlation coefficients (R2) for all the fitted lines were 2': 0.990. The 
profile obtained from water was significantly different from those of excipient 
solutions at all the time points (P < 0.01). The intercepts of water and two excipient 
solutions were also significantly different and they were different from zero (P < 
0.01). The dissolution profiles in the two excipient solutions were however, not 
significantly different at any time point including the intercept (P > 0.05). 
There was no change in solid state (as detected by XRPD shown in Figure 6.6) in the 
dissolution of DH compacts since DH is the thermodynamically stable form in the 
aqueous system. Therefore, the enhancement of the dissolution of CBZ compacts via 
DH needle formation was not observed in the dissolution of the DH compacts. 
Without an obvious surface area influence on the initial dissolution profile, the 
observed dissolution rate of DH compacts in water (0.055 mg L-1 min-1) was much 
lower compared to that from CBZ compacts in the first 150 min (Figure 6.4A). Also, 
the dissolution in water had the slowest observed dissolution rate, i.e. the DH 
compacts showed better dissolution behaviour in the polymer solutions than in water. 
For the solutions containing HPMC and PEG, the surface tension of medium is lower 
than that of water [192, 243-245]. Therefore, wetting of the drug compact in these 
polymer solutions is likely to be increased. The contact angles of DH compacts with 
the three dissolution media provided information of their wetting ability. The angles 
obtained from the HPMC and PEG solutions ( 43 .1 ° and 44. 8° respectively) were 
significantly smaller than that of water (61.0°) (P < 0.01) confirming that wetting 
could have played a role in the improved dissolution of DH compacts in the polymer 
solutions. 
The contact angles obtained from HPMC solution was not significantly different from 
that of PEG solution indicating a similar wetting ability between HPMC and PEG (P 
> 0.05). As seen from the dissolution profiles in Figure 6.4A, the apparent dissolution 
124 
Chapter 6 Influence of hydrate formation on the dissolution of carbamazepine 
rates of DH compacts in HPMC solution (0.178 mg L-1 min-1) was also similar to that 
in PEG solution (0.174 mg L-1 min-1) in the first 150 min. 
While the dissolution in PEG and HPMC solution continued in a fairly linear manner 
between 150 - 240 min, dissolution for the DH compacts dissolved in water showed 
an abrupt increase between 210 and 240 min (Figure 6.4B). This rapid increase was 
very reproducible. From the SEM observations, it can be seen that the morphology of 
the surface of all DH compacts continuously changed during dissolution (Figure 
6.51111). 
(A) 20 min (B) 100 min (C) 240 min 
Figure 6.5 SEM micrographs of initial DH compacts and the compacts recovered 
after dissolution for 20 (A), 100 (B) and 240 min (C): water (11); PEG solution(~); 
and HPMC solution (•). (All photos were taken using the same magnification, bars: 
200 µm). 
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The initial DH compact had a relatively smooth and densely packed surface (Figure 
6.5). With the dissolving of DH needles, the surface roughness increased in the period 
from O - 100 min (Figure 6.5A - B for all samples 11111.A •). At 260 min, morphology 
changes of the surfaces of the compacts became very obvious especially for those 
dissolving in water (Figure 6.5 IIC). This suggests that the dissolution of DH crystals 
from the compact surface may result in a morphology change to a very porous 
structure of the compact, providing an increased surface area for dissolution with an 
increase in dissolution rate (as seen in Figure 6.4B). XRPD confirmed that the porous 
surface structure shown in Figure 6.5 IIIIC was still DH (Figure 6.6). 
5 10 15 20 25 30 35 40 
Diffraction angle [0 2e] 
Figure 6.6 XRPD diffractograms for the intact DH compacts and DH compacts 
recovered (rec.) from three different dissolution media after 240 min dissolution. 
A rapid increase in dissolution after 180 min was not observed for the DH dissolved 
in the PEG and HPMC solutions, and no porous surface structure was detected in 
these compacts even after 260 min (Figure 6.5 JJ.. C and • C). There might be surface 
adsorption of the polymers to the DH compacts which may influence the morphology 
changes of the DH during dissolution, and explain the absence of both the porous 
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structure of the dissolved DH and also a lack of rapid increase in the dissolution 
profiles for the solutions containing HPMC or PEG. 
In Figure 6.4a it was shown that the dissolution rate of DH in water is the lowest of all 
systems measured. In Figure 6.1 it was also shown that the dissolution rate of CBZ in 
HPMC (where CBZ does not convert to the DH) is higher than for any of the 
dissolution rates of DH in Figure 6.4a. This means that unconverted CBZ has a faster 
dissolution than DH and supports the finding that if DH formation on the surface of a 
CBZ tablet (as in case of dissolution of CBZ in water) leads to a higher dissolution 
rate than that of CBZ in HPMC, then this must be due to the increased surface area, 
since DH intrinsically has a lower dissolution rate than CBZ. 
6.4 Chapter summary 
Research in the cunent chapter has investigated the dissolution of CBZ and DH 
compacts in water and two excipient solutions: PEG and HPMC solutions (0.1 % w/v) 
using SEM as an important complementary tool to observe morphology changes 
dming the entire dissolution process. SEM proved to be invaluable for interpretation 
of the results. Although the dissolution of these compacts in various dissolution media 
are all complex processes with many contributing factors (type of crystalline form 
(CBZ or DH), crystal morphology, surface area, and excipient interactions with drug 
particles), the influence and relative importance of these factors on the resulting 
dissolution profiles of CBZ and also DH compacts were clarified. 
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Chapter 7 
Influence of sample characteristics on quantification of 
carbamazepine hydrate formation by X-ray powder diffraction and 
Raman spectroscopy* 
* The work presented in this chapter has been accepted for publication in the European Journal of 
Pharmaceutics and Biopharmaceutics 2006. 
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7.1 Introduction 
The identification and quantitative characterization of crystalline forms of 
pharmaceutical materials are recognized as critical issues in the development of new 
drug products. There is a growing awareness of the significant influence of 
polymorphic and pseudopolymorphic transitions on the physico-chemical properties 
and pharmaceutical performance of drug products [4, 246]. 
There are a number of solid-state characterization techniques, classified by Brittain 
(1995), based on the level at which they probe solid-state properties; ranging from 
molecular to particulate and bulk techniques. Techniques at the particulate level 
include X-ray powder diffraction (XRPD), optical and electron microscopy, and 
thermal methods such as differential scanning calorimetry (DSC). Among these, 
XRPD is a widely employed analytical technique for both qualitative and quantitative 
characterization purposes of crystalline drugs, and its use in this context has been 
reported in many papers [120, 181, 216, 247, 248]. However, it has been pointed out 
that X-rays in a typical XRPD experimental setup only have a small mean penetration 
depth (- 30 µm for Cu Ka radiation) [249] which implies that only a thin sample layer 
is analyzed in the Bragg-Brentano 9/29 geometry which may lead to poor particle 
statistics [250]. Also a range of sample prope1ties such as particle size, packing and 
sample thickness are known to affect the observed X-ray diffraction data [120, 251]. 
Vibrational spectroscopies, such as Raman and IR spectroscopy probe solid-state 
properties at the molecular level. These techniques have been applied in polymorphic 
investigations [136, 172, 206, 234, 252, 253]. The information obtained using Raman 
and IR spectroscopy may be complementary; however, Raman spectroscopy can offer 
some unique advantages over IR which facilitates its application in polymorphic 
investigations [72, 78, 175-177]. As demonstrated in the experimental methods 
section in Chapter 2, Raman spectroscopy only required simple sample preparation, 
and the scattering signal from water is low. These advantages of Raman have also 
been stated in a number of research reports [119, 166, 167]. Raman spectroscopy 
might also be used to identify compounds especially in complex mixtures, as the 
Raman spectra often have fewer and sharper features compared with the respective IR 
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spectra [254]. However, the influence of surface scattering on the Raman signal has 
been widely reported and can significantly affect the outcome of the analysis [174, 
185, 186]. Also, sub-sampling has been reported to be a problem with quantitative 
Raman spectroscopy [165, 168, 255]. Furthermore, two commonly known limitations 
of Raman measurements are sample fluorescence and sample degradation, which 
however, can be avoided in most cases by shifting the excitation wavelength to the 
NIR spectral region [79]. 
It was observed in the study presented in Chapter 6 that during the exposure of CBZ 
(form III) compacts to water, DH was formed and this formation was predominant at 
the surface of the compacts [160]. In this chapter calibration models using binary 
mixtures of CBZ and DH (calibration samples) were built to quantify the amount of 
DH formation on the compacts (compact samples) during the exposure. The main 
aim of this research was to investigate the influence of properties of calibration 
samples and compact samples in polymorph quantification using XRPD and Raman 
methods. Partial least square (PLS) modeling, known to be more robust to 
experimental variations than traditional univariate analysis [256], was used to 
compare XRPD and Raman spectroscopy based CBZ polymorph quantification. A 
specific purpose of this research was to investigate whether there is a surface bias 
using these two techniques and if so, whether this leads to significant impairment in 
the performance of quantitative analyses. 
7.2 Materials and Methods 
7.2.1 Materials 
CBZ form III (Scientific Supplies Ltd, Auckland, NZ) was ground in an oscillatory 
ball mill (Mixer Mill MM301, Retsch GmbH & Co., Germany) for 5 min, and this 
reduced the size of the examined particles to :S 5 µm. XRPD was used to confirm that 
the polymorphic form of CBZ remained unchanged after ball milling and that no 
significant amount of amorphous CBZ was formed. 
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Carbamazepine dihydrate (DH) was prepared using the method specified in Section 
2.1.1. The yield DH was sieved to the size range of 180 - 250 µm (Test sieves, 
Endecotts Ltd., England). DH in the size range of :S 5 µm was produced using the 
same method as described above. XRPD was again used to confirm that DH remained 
unchanged after ball milling. 
7.2.2 Methods 
7.2.2.1. Preparation of calibration samples 
Binary mixtures of CBZ and DH were prepared at 20% (w/w) intervals from O to 100 
% CBZ in DH (200 mg per sample) using geometric mixing. Every mixture was 
prepared in triplicate, and every sample was measured in triplicate. 
7.2.2.2. Preparation of compact samples 
CBZ (200 mg) in the size range of :S 5 µm was weighed and compressed into flat-
faced compacts (12 mm in diameter and 2 mm thickness) using a hydraulic press 
(Model 3392, Freds. Carver Inc., USA) at a pressure of 90 MPa. Compacts were held 
at this pressure for 20 seconds. XPRD was used to confirm that the polymorphic form 
of CBZ (form III) remained unchanged after compression and that no amorphous 
CBZ was formed. 
7.2.2.3. Exposure of compact samples to water 
A six-station dissolution apparatus (D800 dissolution tester, Logan Instrument Corp.) 
with 200 ml distilled water was used. The CBZ compacts were placed at the bottom of 
the dissolution vessels without stirring at room temperature, and recovered after 
predetermined periods of 20 min, 40 min, 60 min, 1440 min, 2880 min and 4320 min. 
CBZ compacts were exposed to water in triplicate for each time interval. The excess 
water on the compact samples was gently adsorbed using a tissue and samples were 
then measured both intact and ground into a powder by XRPD and Raman 
immediately after recovery. Morphology of the DH growing on the surface of 
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compact samples was examined using SEM (see below). For quantitative 
measurements, it was assumed that the dissolution of CBZ or the formed DH had a 
negligible influence on the proportion of the two solid-state form of the drug in the 
compact samples since both CBZ and the formed DH are only very slightly soluble in 
water at room temperature [183]. All compact samples were prepared in triplicate, and 
every sample was measured in triplicate. 
7.2.2.4. X-ray powder diffraction (XRPD) 
XRPD was performed using the method specified in Section 2.2.1. The compact 
samples placed in the dissolution pots were removed at predetermined time points. 
After the excess water on the samples was gently adsorbed using tissue, the whole 
intact compact sample and also its ground powder were then analyzed by XRPD. The 
intact compact samples were placed directly on a flat aluminum sample holder. The 
powdered compact samples were packed into a standard aluminum sample holder and 
measured in the same was as the calibration samples. 
7.2.2.5. Raman spectroscopy 
Raman measurements were conducted using the method specified in Section 2.2.2. 
Calibration samples were measured in aluminum cups, and intact compact samples 
were measured by placing them directly facing the Raman laser. 
7.2.2.6. Scanning electron microscopy (SEM) 
For consistency, the surface of the compact samples facing the top of the dissolution 
pot was chosen for SEM investigation. The excess liquid was removed from the 
compacts as described above and samples were then immediately mounted onto a 
strip of double-sided carbon tape and sputter coated with a thin layer of gold-
palladium under argon vacuum prior to SEM analysis. SEM micrographs were also 
taken of dry intact CBZ and DH compacts, and CBZ and DH powder samples. The 
SEM method employed was specified in Section 2.2.6. 
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7.2.2.7. Thermogravimetric analysis (TGA) 
The excess liquid was removed from the compact samples as described in Section 
7.2.2.4, and then powdered for TGA analysis. The TGA method was specified in 
Section 2.2.5. 
7.2.2. 8. Multivariate analysis 
Multivariate analysis was performed using the method specified in Section 2.2.7. 
7.2.2.9. Statistical tests 
Differences in the quantified values from XRPD and Raman were tested by one-way 
analysis of variance (ANOV A) and Tukey' s pairwise comparisons (significance level 
was 0.05) using Minitab 12.1 software (Minitab Ltd, USA). 
7.3 Results and Discussion 
7.3.1 Particle size and morphology of calibration samples 
Particle size and morphology can greatly influence the exposed surface area of 
crystals and affect the mixing process in the preparation of a calibration curve. This 
may directly affect the linearity of the concentration-response profile when building a 
calibration curve [257]. The pure components of the calibration samples used (CBZ 
and DH) were therefore examined by SEM. The micrographs taken for the pure CBZ 
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Figure 7.1 SEM micrographs of CBZ and DH in two size ranges: 180 - 250 µm (A 
and B); :S 5 µm (C and D). 
Morphology differences between CBZ and DH were clearly apparent in the 
micrographs of samples with a particle size of 180 - 250 µm. CBZ was present as 
prism like crystals whereas DH was present as short needle like crystals. The particle 
size of CBZ and DH crystals was dramatically reduced after grinding, and was mostly 
:S 5 µm (Figure 7 .1 C and D), but differences in morphology between the two solid-
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7.3.2 Particle size and morphology of compact samples 
The morphology of grown DH on the surface of compacts is shown in Figure 7.2. 
Figure 7.2 The morphology of DH growth on the surface of test samples observed by 
SEM. The test samples were recovered after exposure to water for 20 min (A), 40 min 
(B), 60 min (C), 1440 min (D), 2880 min (E) and 4320 min (F). All photos were 
taken using the same magnification, bars: 200 µm. 
The DH concentration on the surface of the compact samples increased with 
increasing exposure time. However, the morphology of DH grown on the surface of 
test samples is different from the DH morphology of the calibration samples (shown 
in Figure 7. lB and D). The DH formed during exposure to water was initially present 
as highly elongated thin needles that aggregated in the first 60 min (Figure 7.2A - C), 
135 
Chapter 7 Influence of sample characteristics on quantitative XRPD and Raman 
and became more densely packed after a longer exposure period of 1440 min (Figure 
7.2D - F). 
7.3.3 Calibration models built using XRPD and Raman spectroscopy 
Following the International Conference on Harmonization, accuracy is defined as the 
closeness of agreement between the reference value and the value predicted from the 
calibration model [258]. In order to achieve a high accuracy of the quantitative 
analysis, various calibration models were built such that the calibration samples had 
properties that more or less closely agreed with those of the compact samples. Firstly, 
the grown DH needles in the compact samples appeared to be highly exposed on the 
surface (Figure 7.2). This situation is obviously different from the situation in the 
calibration samples where DH needles were well mixed with CBZ. Therefore, the 
compact samples were measured both intact (with DH on top of the smface) and 
ground up (with DH mixed with CBZ). Secondly, the DH on the surface of the 
compact samples was of large crystal size. One calibration model was therefore built 
from mixtures of fine form III (::; 5 µm) and large size DH ( 180 - 250 µm) particles. 
The parameters used in generating the calibration models and also the linearity of the 
models are listed in Table 7 - 1. The model prepared using 180 - 250 µm DH crystals 
and::; 5µm CBZ showed very poor linearity when using XRPD (RMSECV was 14.0 
and R2 was 0.832) (Table 7-1). 
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Table 7-1 Parameters used in the generation of the quantitative models. 
Calibration curve 
Form III (::S 5 µm) Form III (::S 5 µm) 
DH (180- 250 µm) DH (::S 5 µm) 
XRPD Raman XRPD Raman 
Pre-processing Multiplicative scattering correction (MSC) 
3300 - 2900 cm-1 3300-2900cm-1 
Regions used 5 - 30° (29) 
1800-400 cm-1 
5 - 30° (29) 
1800-400 cm-1 
Factors used 2 2 2 2 
RMSECV (%) 14.0 2.75 2.93 1.06 
R2 0.832 0.994 0.993 0.999 
There are several potential problems with XRPD when the large crystal size DH (180 
- 250 µm) was used, which could have caused the poor pe1formance of this 
calibration model. Firstly, DH needles are elongated while the form III powder 
consists of prism like crystals with relatively smooth surfaces. Blending was therefore 
difficult as the two solid-state forms of the drug differ in size and morphology. 
Although efforts were made to uniformly blend the DH and CBZ in the calibration 
samples, the mixtures appeared to be inhomogeneous. The same problem was also 
recently reported in a quantitative study canied out by Kipouros et al. [257]. 
Secondly, the maximum acceptable particle sizes of CBZ and DH in quantitative 
XRPD have been calculated according to Brindley's equation [259] and are 15.4 and 
14.1 µm respectively [120]. The X-ray absorption process may be unsatisfactory 
when particles larger than the ideal sizes are used. 
Thirdly, some degree of preferred orientation has been detected by comparing the 
XRPD obtained from the sample when the sample was rotated by 90°. This can hardly 
be avoided in these samples if the large needle-like crystals of DH with size of 180 -
250 µm are present. It has also been reported that preferred orientation could be 
completely overcome only if some comprehensive treatment in both the experimental 
and the analytical approaches were used for instance performing a three-dimensional 
rotation of a capillary sample holder, and employing a two-dimensional detector [260, 
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261]. This however, is not a conventional diffraction geometry and was unavailable in 
this study. 
Fourthly, microabsorption can also be a potential problem. Microabsorption is known 
to stem from differences in the interactions of each material with the X-ray radiation. 
Microabsorption could be a serious problem when a powder mixture has constituents 
with very different particle size [262], as is the case in this calibration model. Lastly, 
in addition to the possible problems listed above, a large particle size can also induce 
primary extinction, leading to an obvious decrease in the diffraction intensity when 
crystalline samples used are large in size and/or have a high degree of imperfection 
[120]. 
On the other hand, the calibration model built using the same large DH/small CBZ 
particle samples showed reasonably good linearity when Raman spectroscopy was 
used (RMSECV (%) 2.75 and R2 0.994). Although there have been some reports 
concerning the influence of particle size on Raman calibration [263, 264], it has also 
been found that the effect can be suppressed under certain conditions such as 
employing proper spectral correction procedures [265]. In this study, sample 
properties, especially particle size, had no significant effect on the calibration model 
obtained from the Raman data, and this was further confirmed by the quantitative 
studies on compact samples presented below. 
The calibration models improved greatly when samples with very fine particle sizes 
(:S: 5 µm) were used, especially for XRPD, where high linearity in the concentration-
response features were obtained as indicated by low values of RMSECV ( < 3.00) and 
high values of R2 (> 0.990) (Table 7-1). The calibration models were shown to be 
physically meaningful by examination of the loading plots. For both the XRPD and 
Raman calibration models the first factor loading plots reflected the spectral 
differences between CBZ and DH. Therefore, these two calibration curves were used 
for quantitative analyses of compact samples presented in the following section. 
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7.4 Characterization of the compact samples using XRPD and Raman 
7.4.1 XRPD 
Figure 7.3 shows the XRPD diffractograms for the initial and also recovered intact 
compact samples after exposure to water. 












5 IO 15 20 25 30 35 
Diffraction angle [0 2ei 
Figure 7.3 XPRD diffractogram of initial compact sample (A), and of recovered 
intact compact samples after exposure to water for 20 min (B), 40 min (C), 60 min 
(D), 1440 min (E), 2880 min (F) and 3240 min (G). 
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The characteristic DH peaks at 8.8° (28) and 12.2° (28) appeared after 20 min, but 
were very small (Figure 7.3B). With increasing exposure time, the DH peaks became 
more prominent (Figure 7.3C - G). In contrast, the characteristic peaks of CBZ 
became smaller with increasing exposure time (Figure 7.3B - D), and only a very 
small peak at 13.0° (28) could be seen after 1440 min exposure (Figure 7.3E). This 
peak was not present at 2880 or 4320 min (Figure 7.3F - G). 
7.4.2 Raman spectroscopy 
Figure 7.4 shows Raman spectra for the initial and also recovered intact compact 
samples after exposure to water. 
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Figure 7.4 Raman spectra of initial compact sample (A) and recovered intact compact 
samples after exposure to water for 20 min (B), 40 min (C), 60 min (D), 1440 min 
(E), 2880 min (F) and 3240 min (G). Areas showing the most obvious differences 
between CBZ and DH are shaded. 
The Raman spectra of the recovered compacts also showed an increasing trend of DH 
formation with increasing exposure time to the water (Figure 7.4). This agreed well 
with the XRPD diffractograms shown above. 
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7.5 Quantification of the compact samples 
The formation of DH in the compact samples quantified both intact and ground into a 
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Figure 7.5 The formation of DH on compact samples during exposure to water as a 
function of exposure time quantified by XRPD (in dashed lines; intact ( •) and powder 
(o)) and Raman spectroscopy (in solid lines; (intact (111) and powder (o)). 
Using Raman spectroscopy (Figure 7.5), there was no significant difference in the 
quantified DH amount between intact and powdered compact samples at all time 
points (P > 0.05). This showed that there was a good penetration of the Raman laser 
into the sample. For XRPD, significant differences between intact and powdered 
compact samples were seen for the first two time points (20 and 40 min) (P < 0.05), 
but with increasing formation of DH on the test sample, the predicted values became 
similar (P > 0.05). One plausible explanation for this difference could be the 
penetration problem of the X-ray beam as described in the introduction. The higher 
predicted amount of DH from the intact compact samples than from the powdered 
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ones might be due to its higher exposure to the X-ray beam when orientated on the 
surface of the sample instead of being well mixed in a powdered one, which then 
leads to an over-represented signal in XRPD. 
There was a significant difference in the predicted values between Raman and XRPD 
methods (P < 0.05). The percent weight loss of the compact sample recovered after 
4320 min exposure was measured by TGA. The value obtained was 13.52 % ± 0.07 
(w/w) (mean ± SD, n = 3). This is in excellent agreement with the theoretical water 
content in pure DH (13.2 % (w/w)) [181]. Therefore, TGA confirmed that the 
compact sample had totally converted to the DH, and thus supported the value 
obtained from Raman spectroscopy and indicated an under-prediction in XRPD. 
As described above, the morphology and particle size of DH grown on the surface of 
the compact samples is different from the DH of the calibration samples, where also 
problems such as preferred orientation are likely to be induced in the X-ray 
diffractrogram of needle-like DH samples. Therefore, for a deeper understanding of 
the under-prediction in XRPD, the compact samples recovered after a long exposure 
of 4320 min was measured both intact and powdered are plotted together with 
calibration DH samples of the two different particle size ranges (Figure 7 .6). 
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Figure 7.6 XRPD diffractograms of pure DH calibration samples in size range of 180 
- 250 µm (A) and :S 5 µm (B), and the compact samples recovered after a long 
exposure of 4320 min (powdered (C) and intact (D)). Areas showing particularly 
obvious differences in the diffractograms between calibration and test samples are 
shaded. 
The diffractograms were almost identical for the compact samples measured either 
intact or ground into a powder (Figure 7C and D). However, obvious peak pattern 
differences in the diffractograms between DH grown from the compact samples and 
the DH calibration samples could be observed, especially in the shaded areas (19.2 -
19.9° (28) and 23.9 - 25.0° (28)). Also, the X-ray patterns between the calibration DH 
samples of two different particle size (Figure 7A and B) were different at 8.9° (28) 
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and 12.4° (28) and also in the shaded areas. Therefore, it should be noted that crystal 
size itself in this study could influence the relative peak intensities in the XPRD 
measurements. Although it is hard to determine the exact reasons for the differences 
in the relative peak intensities between the DH samples used in the calibration models 
and the compact samples, particle size and morphology differences could both be 
possible explanations, where problems as preferred orientation might contribute to the 
different relative peak intensities. 
For a better comparison, Raman spectra of these samples were also checked. In 
contrast to the diffractograms described above, the Raman spectra were very 
consistent among all the DH samples (Figure 7.7), regardless if calibration or compact 
samples. 
3000 1200 1000 800 600 
Wavenumber [cm-1] 
Figure 7.7 Raman spectra of pure DH calibration samples in size range of 180 - 250 
µm (A) and ::S 5 µm (B), the compact samples were recovered after a long exposure 
time of 4320 min (powder (C) and intact (D)). 
To improve the accuracy of the calibration model for the compact samples, the 
specific diffraction angles range of 19.2 - 19.9° (28) and 23.9 - 25.0° (28) in the 
XRPD diffractograms were excluded from building the calibration curve, and the 
parameters used in generating the new calibration model are listed below in Table 7-2. 
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The predicted values for compact samples from this new calibration curve are plotted 
together with those gained from Raman spectroscopy for a clearer comparison (Figure 
7.8). 
Table 7-2 Parameters used in the generation of the quantitative models. 
Calibration curve 
Form III (:5 5 µm) 
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Figure 7.8 The formation of DH on the CBZ compacts during exposure to water as a 
function of exposure time quantified by new calibration model in XRPD (in dashed 
lines; intact compacts ( •) and powdery compacts ( o )) and Raman spectroscopy (in 
solid lines; (intact compacts (11) and powdery compacts (o)). 
The values predicted from XRPD for the last three time points (1440 - 4320 min) 
greatly increased and became not significantly different from those obtained by 
Raman spectroscopy (P > 0.05). However, the values obtained in the initial 60 min 
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were still significantly different from those determined by Raman spectroscopy (P < 
0.05). 
7.6 Chapter summary 
It is shown in the present study that both XRPD and Raman spectroscopy combined 
with PLS could in principle be used to evaluate the polymorphic conversion of CBZ 
compacts to the DH. However, Raman spectroscopy appeared to be a more reliable 
quantification method because problems such as different particle size, morphology 
and spatial distribution of the two solid state forms of the drug seemed to have no 
significant influence on Raman scattering in this study. The robust nature of Raman 
analysis greatly facilitates the whole quantification process from the preparation of 
calibration models to the quantification of in situ CBZ-DH conversion. 
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The research presented in this thesis investigated various aspects concerning the 
conversion of CBZ to the DH in a water containing environment. The two major 
research aspects of this research were: (I) understanding the phase transformation of 
CBZ in aqueous suspension both in the absence and presence of excipients, and (2) 
evaluating the potential of Raman spectroscopy in probing polymorphic phase 
transformations of pharmaceutical materials in aqueous environment. 
8.1 Carbamazepine 
A deeper understanding of the transformation behavior of CBZ is imp01tant since not 
only is such transformation possible during the storage of commercial CBZ tablets, 
but it is also expected that a part of the drug will convert to the DH during the 
manufacture of CBZ tablets when exposed to moisture. 
The phase transformation of CBZ forms III, II and I (individually and a mixture of 
forms III and I) to the DH in aqueous suspension has been characterized in this 
research (Chapter 3). Raman spectroscopy combined with partial least squares 
analysis (PLS) was used to generate quantitative models of binary and ternary 
mixtures of the different CBZ forms with the DH. The results showed that all the 
calibration models built had a good predictive ability (RMSECV were less than 8 %). 
The transformation process of the CBZ forms studied could be well fitted by a first 
order kinetics with an unconverted portion (R2 2: 0.95). The unconverted portions 
ranged from 16 % to 51 % after dispersion for 210 min. The influence of several 
factors such as internal crystalline structure (polymorphic form), crystal morphology 
and particle size on the transformation has also been evaluated. When two batches of 
CBZ form I with different morphology were used, their conversion kinetics differed 
significantly. However, different CBZ forms (forms III and I) which had similar 
crystal morphology exhibited similar transformation kinetics. Furthermore, the 
conversion of forms III and I in the aqueous suspension was not affected by the 
presence of the respective other polymorph when dispersed together. 
To achieve a further understanding of the hydrate formation process of CBZ 
anhydrate (form III), visual observation using scanning electron microscopy (SEM) 
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was employed as a principal investigative method in this work where information 
about the phase transformation was obtained from a different perspective from that 
explored by Raman spectroscopy. It was observed that defect structures were a more 
important driving force than the nature of different crystal faces for the initiation of 
the hydrate formation. However, clear differences in the hydrate formation process 
among the CBZ crystal faces were also detected, where the biggest crystal face grown 
from methanol, (100), was the slowest one to be covered with DH needles. Because 
the hydrate formation is achieved by hydrogen bonding between CBZ and water 
molecules, the molecular arrangements along three defined crystal faces [(100), (010) 
and (001)] were examined using a crystal structure visualization software. Fewer 
polar groups exposed on the (100) face than on the (001) and (010) faces were found, 
which explained the comparatively weak interaction of the (100) face with water 
during hydrate formation. 
Research has been conducted on the effect of different excipients on the phase 
transformation of CBZ to DH in suspension because excipients are commonly 
employed in the pharmaceutical formulations. This research was also carried out by 
two main approaches: characterization using spectroscopic and diffractometric bulk 
techniques and visual observation using electron microscopic techniques. 
An initial study (Chapter 4) investigated ten different excipients, where the excipients 
with similar chemical structures have been grouped together (group 1: 
methylcellulose (MC), hydroxypropyl methylcellulose (HPMC), hydroxypropyl 
cellulose (HPC), 2-hydroxyethyl cellulose (HEC), sodium carboxymethyl cellulose 
(CMC), cellobiose; group 2: poly(vinyl pyrrolidone) (PVP), polyvinyl pyrrolidone-
vinyl acetate copolymer (PVPN A) and N-methyl-2-pyrrolidone; group 3: 
polyethylene glycol (PEG) and polyethylene oxide-polypropylene oxide copolymer 
(PEO/PPO)). CBZ polymorphic forms III and I were dispersed separately into each 
aqueous excipient solution (0.1 % w/v) for 30 min at room temperature. The 
inhibition effect of each excipient was quantified using Raman spectroscopy 
combined with PLS. The solubility parameter of each excipient was also calculated 
and used for interpreting the data. Excipients in groups 1 and 2 which have both low 
solubility parameters(< 27.0 MPa112) and strong hydrogen bonding groups inhibited 
the conversion completely. With increasing solubility parameter, the inhibition effect 
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decreased for group 1 excipients, especially for CBZ form I, which has a higher 
specific surface area. Also, the excipients of group 3 lacking strong hydrogen bonding 
groups showed poor inhibition although they have low solubility parameters (< 21.0 
MPa112). The results implied that both hydrogen bonding interaction between the 
excipient and CBZ and also surface adsorption of excipient onto CBZ particles 
induced by hydrophobic interaction (expressed by calculated solubility parameter) are 
important to the inhibition ability of the excipients in aqueous suspension. 
Although differences in the inhibition ability among the three different classes of 
excipients on the hydrate formation of CBZ were observed when a very low 
concentration of excipients (0.1 % w/v) and a relatively short dispersion length (30 
min) were used, examination of varying conditions e.g. concentrations of the 
excipient, suspending time and temperature might provide deeper insight into the 
differences among the excipients showing similar inhibition effects in this research. 
Clarifying the specific interacting groups of the excipient and CBZ in the suspension 
may also be ideal for a thorough understanding of the interaction mechanism. 
Moreover, further research on other drugs having similar chemical structure as CBZ 
might be useful. A similar trend in the inhibition ability of these excipients for other 
drugs might also be observed as the explanations presented above are very likely to be 
applicable more generally. 
The data shown in Chapter 5 resulted from a direct observation of the excipient' s 
influence using the imaging technique, SEM. Two strong and weak inhibitors from 
the initial study were selected. The inhibition ability of these excipients was again 
confirmed. No conversion of CBZ to the DH was found after 18 hours immersion in 
the solution containing HPC or PVP (0.1 % w/v) although the crystal size of CBZ 
decreased suggesting the dissolving of CBZ crystals in the solution. PEG and CMC 
(pH = 7.5) were less potent inhibitors than HPC and PVP, and DH needles were 
observed on all the faces except the (100) face after 18 hours immersion. The 
potential application of microscopical techniques in solid state analysis including 
phase transformation, particle size and morphology studies were clearly demonstrated 
in this work. In fact, it can be concluded that microscopy should be more extensively 
applied in pharmaceutical area spanning from the early state drug discovery to late 
development stages. 
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Although the transformation from different CBZ polymorphic forms to the DH has 
been clarified in this work, further work on the dehydration behavior of DH is also 
necessary for a thorough understanding of physico-chemical properties of CBZ. 
Several papers have reported the dehydration profile of DH as well as the effect of 
drying conditions on properties such as water vapour adsorption and dissolution rate 
of the resulting CBZ anhydrate [216, 266, 267]. The starting material however was in 
a dry/semi-dry condition in all these studies, and employing a similar aqueous 
environment to the DH in commercial suspension may be more practically useful. 
Also, the presence of excipients in the suspension during dehydration could be 
expected to have a significant influence on the properties of the resulting anhydrate 
since considerable effects of excipients on the hydrate formation of CBZ were 
observed when they were suspended together (as described above). Therefore, 
excipient effects on the dehydration behaviour of DH should also be investigated. 
Research in this thesis has focused on one important influence factor, solid state phase 
transformation, on the in vitro dissolution profiles of a drug in the formulation. The 
influence of phase transformation on in vitro dissolution tests has hardly received any 
attention from either solid state or in vitro dissolution researchers although a number 
of dissolution tests have been canied out on drugs having different polymorphs and 
also hydrates [155, 157, 180, 191]. Very recently, phase transformations of 
theophylline and nitrofurantoin during in vitro dissolution tests have been reported 
[70]. In the experiments of this work (Chapter 6), dissolution tests of CBZ and DH 
compacts were performed separately in three different dissolution media: distilled 
water, hydroxypropyl methylcellulose (HPMC) and polyethylene glycol (PEG) 
solutions (0.1 % w/v). It was found that for the CBZ compacts, the dissolution rate of 
the drug in water was fastest (0.338 mgL-1min-1). With increasing ability of the 
excipients to inhibit the hydrate formation of CBZ (PEG < HPMC), surprisingly the 
dissolution rate of CBZ compacts decreased: PEG solution (0.314 mgL-1min-1) > 
HPMC solution (0.257 mgL-1min-1). For the DH compacts, the dissolution rate in 
water (0.055 mgL-1min-1) was slower than that of PEG and HPMC solutions (0.174 
and 0.178 mgL-1min-1 respectively). The contact angle measurements showed a 
significantly higher value in water (61.0°) than in PEG and HPMC solutions (44.8° 
and 43.1 ° respectively). The results suggested that for the dissolution profiles not only 
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the influence of solubility changes due to phase transformation should be considered, 
but also the subsequent changes resulting from transformation such as crystal 
morphology, surface area and excipient interaction have to be taken into account. 
Further work could investigate the in vitro dissolution behavior of various drugs 
which may undergo phase transformation during dissolution. In these studies different 
dissolution and solid state approaches such as spectroscopical techniques with the 
potential for in-line characterization of solid state phase composition during 
dissolution would be valuable. The ultimate goal of in vitro dissolution studies is to 
establish a reliable correlation between in vitro drug release information and in vivo 
drug profiles [268], and thus a good understanding of influencing factors on the 
dissolution process is essential. 
8.2 Raman spectroscopy 
Raman spectroscopy has been extensively applied in this research, and has been 
demonstrated to be a powerful analytical tool for solid state investigations, 
particularly for aqueous systems. 
Because of the weak water scattering and minimal sample preparation in Raman 
measurements, the phase transformation of different CBZ polymorphic forms in 
aqueous environment could be effectively monitored. It was also illustrated that even 
for a complex polymorphic system containing a mixture of two different polymorphic 
forms of CBZ (forms III and I) as the starting material, Raman spectroscopy was still 
able to detect the transformation process of each form in the suspension (Chapter 3). 
This also holds true for the suspension of CBZ (polymorphic form III or I) containing 
excipients, where identification of the polymorphic form of the drug during 
transformation could be obtained without influence from the presence of excipient or 
water (Chapter 4). It has to be emphasized that Raman measurements are often fast 
and noninvasive, which are particularly important factors for detecting the appearance 
of metastable forms during phase transformation. 
The development of multivariate analytical models (PLS) enabled a robust and 
widespread application of Raman to quantitative analysis. A study aimed at 
153 
Chapter 8 General discussion and future considerations 
comparing the suitability of powder X-ray diffraction (XRPD) and Raman 
spectroscopy in identifying and quantifying polymorphic mixtures of CBZ and DH 
was also conducted in the current work (Chapter 7). The influence of particle size, 
particle morphology, mixing, and in particular, surface bias on quantitation was also 
investigated. Binary mixtures of CBZ anhydrate (form III) and DH were prepared and 
analysed using both XRPD and Raman spectroscopy in combination with PLS 
analysis. The results showed that in principle both XRPD and Raman spectroscopy 
could be used to build calibration models for quantitative analysis, and a satisfactory 
correlation between the two techniques could be achieved. Raman spectroscopy 
however appeared to be a more reliable quantification method because problems such 
as different particle size, morphology, and spatial distribution of the two solid state 
forms of the drug had no significant influence on Raman scattering. The study clearly 
demonstrated that Raman analysis is a robust technique which could greatly facilitate 
the whole quantification process from the preparation of calibration models to the 
quantification of polymorphic mixtures. 
Raman microscopy combining molecular analysis capabilities of Raman spectroscopy 
with the visualization power of optical microscopy has also been applied in this work. 
The localization as well as molecular structure of CBZ and DH on the surface of a 
single CBZ crystal was rapidly identified using Raman microscopy (Chapter 5) while 
the crystal integrity was preserved. 
In summary, the work presented in this thesis has demonstrated the potential of 
Raman spectroscopy in future studies. Raman spectroscopy can be used for 
polymorph quantification under various conditions including liquid samples and 
slurries. Sample preparation is minimal, and may even be unnecessary if a Raman 
probe is employed in situ, and more importantly the analysis is robust to material 
properties. These unique advantages of Raman spectroscopy make it a feasible 
technique for analyzing versatile pharmaceutical systems at the molecular level. 
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